



Effective 5/1/2026

Area Medical Policy
Lines Of All Lines of
Business Business

Proprietary Laboratory Testing

PURPOSE:

This policy addresses emerging technology surrounding proprietary laboratory testing. Providers are encouraged to check eligibility and benefits prior to submitting any request for proprietary lab work as some plans limit certain types of testing, such as genetic testing.

DEFINITIONS:

NCCN- National Comprehensive Cancer Network. It is a non profit organization focusing on research, patient care, and education. The organization develops resources, expert recommendations, and guidelines related to cancer care.

NCCN as a Category 1, 2A or 2B Level of Evidence and Consensus

- Category 1: Based upon high-level evidence there is uniform NCCN consensus that the intervention is appropriate.
- Category 2A: Based upon lower-level evidence there is uniform NCCN consensus that the intervention is appropriate.
- Category 2B: Based upon lower-level evidence without a uniform consensus but with no major disagreement that the intervention is appropriate.
- Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

CLIA- The Clinical Laboratory Improvement Amendments

COVERAGE POLICY:

At the time of the initial release of Proprietary Laboratory Testing (PLA) codes where there is insufficient peer review literature or evidence based guidelines available to determine the value of the testing regarding clinical efficacy, safety, or applicability to clinical practice, and to what extent a specific test supports clinical decision making, or has demonstrated a definitive positive impact on clinical outcomes, those tests will be considered

experimental and investigational. Proprietary Laboratory Test Codes that have a status of experimental/ investigational are excluded from coverage.

The listings below are not intended to be all inclusive. Please check with The Health Plan regarding precertification requirements if a Proprietary Lab test is not found listed in this policy or on the Prior Authorization List on the Internet.

Providers are reminded to use correct coding for requested tests for the appropriate date of service.

For any of the allowed tests to be covered:

- The specific test is a covered benefit per specific line of business and/or plan design.
- Overly broad multi-gene panels may not be covered under certain lines of business.
- Some tests are only allowed once per lifetime.
- Tests, whether single or part of a panel, will not be covered if duplicative. Providers should be aware if the member has undergone previous genetic testing in order to avoid denials.
- Most tests are not covered when used as a screening tool in the general population. There must be specific signs and/or symptoms or an existing diagnosis indicating a clinical need for the test.
- The lab providing the test is responsible for clearly indicating to treating physicians the population and indication(s) for test use.
- Tests must be performed in CLIA-certified laboratory.
- The testing must be approved by the US Food and Drug Administration and indication(s) for the test must be supported based on published, peer-reviewed prospective evidence.
- The test will provide information that will impact plan of care and guide therapy.
- If applicable, the testing is using molecular biomarkers that has not been previously performed for predictive therapy selection.
- Testing is performed according to the intended use of the test in the intended patient population for which the test was developed and validated.
- If specific criteria is not indicated here for individual tests, The Health Plan will utilize InterQual Criteria or the appropriate Medicare NCD/LCD depending on product line.

Proprietary Lab Tests Requiring Precertification:

- **Precertification Requirements do not imply coverage as some tests may not be covered for all lines of business. Please check corresponding fee schedules and plan documents for line of business prior to requesting review.**

Abbott Alinity™ m HSV 1&2/VZV Assay (Abbott Molecular, Inc)

Abbott Alinity™ m STI CT/NG/TV/MG and CT/NG/TV Assays (Abbott Molecular, Inc)

AlloSure® (CareDx® Laboratory, CareDx®, Inc)

Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping (Quest Diagnostics®)

Augusta Hematology Optical Genome Mapping (Georgia Esoteric and Molecular Labs, Augusta University, Bionano)

Augusta Optical Genome Mapping (Georgia Esoteric and Molecular (GEM) Laboratory, LLC)

Avantect™ Pancreatic Cancer Test (ClearNote™ Health)

Aventa FusionPlus™ (Aventa Genomics, LLC)

Barontella ddPCR (Galaxy Diagnostics, Inc)

Barontella Digital ePCR™ (Galaxy Diagnostics, Inc)

BCRAplus (Ambry Genetics)

BioFire® Respiratory Panel 2.1(RP2.1) and BioFire® FilmArray Pneumonia (PN) Panel (bioMérieux)

- Covered for members with signs/symptoms of respiratory infection and are immunocompromised and considered high risk for complications.
- May not be covered for all LOB.

BIOFIRE® SPOTFIRE® Respiratory/Sore Throat(R/ST) Panel – Respiratory Menu (bioMérieux)

BIOFIRE® SPOTFIRE® Respiratory/Sore Throat(R/ST) Panel – Sore Throat Menu (bioMérieux)

BreastNext® (Ambry Genetics®) Deleted 01/01/2026

BTG Early Detection of Pancreatic Cancer (Breakthrough Genomics)- Currently may only be covered for certain Medicare plans.

CARDIO inCode-Score (CIC-SCORE) (GENinCode U.S. Inc)

CardioRisk+ (Gene by Gene, LTD) (OpenDNA, LTD)

Caris Assure™ (Caris MPI, Inc d/b/a Caris Life Sciences®)

CELLSEARCH® HER2 Circulating Tumor Cell (CTC- HER2) Test (Menarini Silicon Biosystems, Inc)- May not be covered for all lines of business

Chromosome Genome Mapping (UR Medicine Labs, Bioano Genomics, Inc)

Ciprofloxacin Susceptibility of Neisseria Gonorrhoea (MedArbor Diagnostics, SpeedX, Inc)

Clarifi™ (Quadrant Biosciences, Inc)

CNT (CEP72, TPMT, and NUDT15) genotyping panel (RPRD Diagnostics)

ColoScape™ Colorectal Cancer Detection (DiaCarta Clinical Lab, DiaCarta, Inc) - May only be covered for Medicare plans

ColoNext® (Ambry Genetics®)

clonoSEQ® Assay (Adaptive Biotechnologies)

Comprehensive Screen (Aspenti Health) - Covered only for certain Medicare plans at this time

CRCdx® RAS Mutation Detection Kit (EntroGen, Inc)

- This test is the analysis of variants of the KRAS and NRAS genes.
- Considered medically necessary when used to aid in the identification of colorectal cancer patients for treatment with Vectibix® (panitumumab). As of the date of this policy origination, this is the only approved indication.

DecisionDx® DiffDx™- Melanoma (Castle Biosciences, Inc)

DH Optical Genome Mapping/Digital Karyotyping Assay (The Clinical Genomics and Advanced Technology)

(CGAT) Laboratory at Dartmouth Health, Bionano Genomics)

Elecsys® PhosphoTau (181P) CSF(pTau181) and B- Amyloid (1-42) CSF II (Abeta 42) Ratio (Roche Diagnostics Operations)

Elecsys® Total-Tau CSF (tTau) and B- Amyloid(1-42) CFS II (Abeta 42) (Roche Diagnostics Operations)

- Elecsys® PhosphoTau (181P) CSF(pTau181) and B -Amyloid (1-42) CSF II (Abeta 42) Ratio or Elecsys® Total-Tau CSF (tTau) and B- Amyloid(1-42) CFS II (Abeta 42) may be covered for members with a diagnosis of Alzheimer's disease where treatment with amyloid beta targeting therapy (e. g. lecanemab-irimb [Leqembi™] or idonanemab-azbt [Kisunla]) is being considered.
- Not covered for any other indication at this time.

Epi+gene CHD™ (CardioDiagnostics, Inc)

EpiSign Complete (Greenwood Genetic Center)

Episwitch® CiRT (Checkpoint-Inhibitor response Test) (Next Bio-Research Services, LLC. Oxford Biodynamics, PLC)

EpiSwitch® Prostate Screening Test (Oxford Biodynamics, Inc)

ERA® Endometrial Receptivity Analysis (Igenomix® USA)

ESOPREDICT® Barrett's Esophagus Risk Classifier Assay (Capsulomics, Inc d/b/a Previsse) - Currently only covered for certain Medicare plans at this time.

Eurofins TRAC™ dd-cfDNA (Transplant Genomics, Inc)

ExaCT-1 Whole Exome Testing (Lab of Oncology- Molecular Detection, Weill Cornell Medicine-Clinical Genomics Laboratory)

Foundation One CDx™ (F1CDx) (Foundation Medicine ,Inc)

Foundation®One Liquid CDx (Foundation Medicine, Inc)

Genomic Prostate Score® (GPS) Test (MDxHealth, Inc)

Genomic Unity® 2.0, (Variantyx Inc)

Genomic Unity® Ataxia and Comprehensive Repeat Expansion and Sequence Analysis (Variantyx Inc)

Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (Variantyx Inc)

Genomic Unity® DMD Analysis (Variantyx Inc)

Genomic Unity® Whole Genome Analysis- Proband, Comparator (Variantyx Inc)

Genomic Unity® Exome Plus Analysis- Proband, Comparator (Variantyx Inc)

Genomind® Pharmacogenetics Report (Genomind®, Inc) May only be covered for certain Medicare plans

Genomind® Professional PGx Express™ CORE (Genomind®, Inc) May only be covered for certain Medicare plans

GeneticsNow® Comprehensive Germline Panel (GoPath Diagnostics, Inc)

GeneSight® Psychotropic and ADHD tests (Assurex Health, Inc, Myriad Genetics, Inc) 0345U must be billed for all LOB for these tests.

Genesys Carrier Panel (Genesys Diagnostics, Inc)

Guardant360®, Guardant360 Response™, Guardant360® CDx , and Guardant360 Tissue Next™ Tests (Guardant Health, Inc)

IDgenetix® (Castle Biosciences, Inc)

IDH1, IDH2, and TERT Mutation Analysis, (NGS), Tumor (IDTRT) (Mayo Clinic)

Insight TNBCtype™ (Insight Molecular Labs)

InVisionFirst®-Lung Liquid Biopsy (Inivata, Inc)- May only be covered for Medicare plans

Invitae PCM MRD Monitoring (Invitae Corporation)

Invitae PCM Tissue Profiling and MRD baseline Assay (Invitae Corporation)

IriSight™ Prenatal Analysis- Proband and Comparator Tests (Variantyx, Inc)

IsoPSA® (Cleveland Diagnostics, Inc)

Karius® Test (Karius Inc)

KawasakiDx (OncoOmicDx Laboratory, mProbe)

kidneyintelX (Renalytix, Inc, NYC, NY) - Test is not covered as a screening or standalone diagnostic

kidneyintelX.dkd™ (Renalytix, Inc, NYC, NY)- Test is not covered as a screening or standalone diagnostic

Lifetime Genomics Risk Assessment (GenomicMD, Inc)

LiquidHALLMARK® (Lucence Health) both codes 0409U and 0530U

LiquidHALLMARK® ctDNA and ctRNA, (Lucence Health, Inc) 0571U.

Lung HDPCR™ (Protean BioDiagnostics)

LungLB® (LungLife AI®)

Lymph3Cx Lymphoma Molecular Subtyping Assay (Mayo Clinic)

Macrolide Resistance of Mycoplasma Genitalium (MedArbor Diagnostics, Speedx, Inc)

Medication Management Neuropsychiatric Panel (RCA Laboratory Services LLC d/b/a GENETWORx)

MI Cancer Seek™ NGS Analysis (Caris MPI d/b/a Caris Life Sciences)

MindX Blood Test™- Memory/Alzheimers, Mood, Pain, Stress, Suicidality, and Longevity (MindX™ Sciences)

Mind Px (Mindera Corporation) -Limited coverage

miR-31 now™ (GoPath Laboratories)

miR Sentinel™ Prostate Cancer Test (miR Scientific, LLC) Codes 0343U and 0424U

Molecular Microscope® MMDx-Heart (Kashi Clinical Laboratories)

Molecular Microscope® MMDx-Kidney (Kashi Clinical Laboratories)

M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry (Mayo Clinic)

- Covered for evaluation and management of plasma cell dyscrasias.

MSK-IMPACT Integrated Mutation Profiling of Actionable Cancer Targets (Memorial Sloan Kettering Cancer Center)

MyAML, NGS Panel (LabPMM, LLC)

myChoice® CDx (Myriad Genetics)

MYCODART-PCR™ Dual Amplification Real Time PCR Panel for 4 Aspergillus species (RealTime Laboratories, Inc/MycoDART, Inc)

MYCODART-PCR™ Dual Amplification Real Time PCR Panel for 6 Candida species (RealTime Laboratories, Inc/MycoDART, Inc)

MyGenVar Pharmacogenomics Test (Geisinger Medical Laboratories)

MyMRD® NGS Panel (Laboratory for Personalized Molecular Medicine)

myPath® Melanoma (Castle Biosciences, Inc)

MyProstateScore and MyProstateScore 2.0 (LynxDX)

myTAIHEART (TAI Diagnostics, INC)

mRNA CancerDetect™ (Viome Life Sciences, Inc)

NavDx® (Naveris, Inc)

NextGen Precision™ Testing (Precision Diagnostics LBN Precision Toxicology, LLC)

NorthStar Response™ (cell-free circulating DNA) (BillionToOne, Inc)

NorthStar Select™ (cell-free circulating DNA) (BillionToOne, Inc)

NT (NUDT15 and TPMT) genotyping panel (RPRD Diagnostics)

Oncomap™ ExTra (Exact Sciences, Inc, Genomic Health Inc)

OncoMine™ DX Target Test (Thermo Fisher Scientific)

OncoReveal™ CDx (Pillar Biosciences, Inc)

Oncotype MAP™ Pan-Cancer Tissue Test (Paradigm Diagnostics)

OvaNext® (Ambry Genetics®)

OncoSignal 7 Pathway Signal (Protean BioDiagnostics)

OncoTarget/OncoTreat (Columbia University Department of Pathology and Cell Biology, Darwin Health) - May only be covered for Medicare plans

Oncotype DX® Breast DCIS Score™ Test (Genomic Health, Inc)

PancreaSeq® Genomic Classifier (Molecular and Genomic Pathology Laboratory, University of Pittsburgh Medical Center) - Potential Experimental and Investigational

PGDx elio™ tissue complete (Personal Genome Diagnostics, Inc)

PGT-M, Igenomix® (Part of Vitrolife Group™ Igenomix®)

Praxis Optical Genome Mapping, (Praxis Genomics, LLC)- May only be covered for certain Medicare plans

Praxis Whole Genome and Somatic Whole Genome Sequencing tests (Praxis Genomics LLC) - May only be covered for certain Medicare plans

Praxis Transcriptome and Somatic Transcriptome (PraxisGenomics LLC)- May only be covered for certain Medicare plans

Praxis Combined Whole and Somatic Combined Whole Genome Sequencing and Optical and Somatic Optical Genome Mapping (Praxis Genomics) - May only be covered for certain Medicare plans

PreciseType® HEA Test (Immucor, Inc)

PrecisionCHD™ (Cardio Diagnostics, Inc)

ProstateNow™ Prostate Germline Panel (GoPath Diagnostics, Inc)

QClamp® Plex VEXAS UBA1 Mutation Test (DiaCarta, Inc)

Qlear UTI and Qlear UTI – Reflex ABR (Lifescan Labs of Illinois, Thermo Fisher Scientific)- May only be covered for certain Medicare plans

QuantiVirus™ HPV E6/E7 mRNA tests for Cervical Cancer (DiaCarta, Inc)

RadTox™ cfDNA test ((DiaCarta Inc)

Rapid Genome Sequencing Test (University of California San Francisco Genomic Medicine Laboratory)

Rapid Whole Genome Sequencing (Mayo Clinic)

Rapid Genome Sequencing Family Member Comparator (Mayo Clinic) - use with code 0582U.

RCIGM Rapid Whole Genome Sequencing (Rady Children's Institute for Genomic Medicine)

RCIGM Ultra-Rapid Whole Genome Sequencing (Rady Children's Institute for Genomic Medicine)

Rh Test (Natera™)- All of the following indications must be met for coverage:

- Pregnancy may be at risk for alloimmunization due to maternal RhD status or the presence of red cell antigen antibodies; *and*
- Paternal antigen typing is unavailable or heterozygous; *and*
- Amniocentesis is declined or contraindicated.

RightMed® Mental Health Gene Report and Mental Health Medication Report (OneOme LLC)

RightMed® Comprehensive Test and Comprehensive Test Exclude F2 and F5 (OneOme LLC)- May only be covered for Medicare plans

RightMed® Gene Test Exclude F2 and F5 (OneOme® LLC)

RightMed® Oncology Gene and Oncology Medication Reports (OneOme® LLC)

RightMed® PGx16 Test and Gene Report (OneOme®, LLC)

Risk Reveal™ (Razor Genomics)

Salimetrics® Salivary Melatonin Profile (Salimetrics® LLC)

- May be covered to R/O Cushings Syndrome.

- Include signs, symptoms, or clinical support why the member is being tested for Cushing's Syndrome.
- **Note:** Salivary cortisol collected in the evening for the diagnosis of Cushing's Syndrome is currently the only covered application of hormone measurement in salivary fluid. Any other request of salivary hormones measurements will be denied as experimental and investigational.

SelectMDx® for Prostate Cancer (MDx Health®, Inc)

Sentosa® SQ HIV-1 Genotyping Assay (Vela Operations Singapore Pte, Ltd)- Covered for Medicare members only

Signatera™ (Natera, Inc)- Only covered for Medicare plans

SMASH™ (New York Genome Center, Marvel Genomics)

Solid Tumor Expanded Panel (Quest Diagnostics®)

Strata Select™ (Strata Oncology, Inc)

Tempus nP (Tempus Labs, Inc) May only be covered for certain Medicare plans

ThyGeNEXT® Thyroid Oncogene Panel (Interspace Diagnostics)

ThyraMIR™ (Interspace Diagnostics)

Thyroid GuidePx® (Protean BioDiagnostics, Qualisure Diagnostics)

ThyroSeq® CRC (CBLPath, Inc, University of Pittsburgh Medical Center)- Potential Experimental and Investigational

Thyroseq Genomic Classifier (CBL Path, Inc)

ToxLok™ (inSource Diagnostics)

TruSight™ Oncology Comprehensive (Illumina, Inc)

Tuteva™ (Verici Dx, Inc)

UCGSL RFC1 Repeat Expansion Test (University of Chicago Genetic Services Laboratories)

Unity Carrier Screen™ (BillionToOne, Inc)

UCSF Pharmacogenomics Panel (University of California San Francisco Genomic Medicine Laboratory)

Vasistera™ (Natera, Inc)

Versiti™ aHUS Genetic Evaluation (Versiti™ Diagnostic Laboratories)

Versiti™ Autosomal Dominant Thrombocytopenia, Inherited Thrombocytopenia, Thrombosis, Coagulation Disorder Panels (Versiti™ Diagnostic Laboratories)

Versiti™ Congenital Neutropenia, Comprehensive Bleeding, Fibrinolytic, Comprehensive Platelet Disorder Panels (Versiti™ Diagnostic Laboratories)

Versiti™ VWD Type 2B Evaluation Tests (Versiti™ Diagnostic Laboratories)

Versiti™ VWF Collagen III and IV, and VWF Type 2N Binding Tests (Versiti™ Diagnostic Laboratories)

Versiti™ VWF Propeptide Antigen (Versiti™ Diagnostic Laboratories)

Versiti™ Red Cell Genotyping Panel (Versiti™ Diagnostic Laboratories)

VitaGraft™ Kidney 2.0 (Oncocyte Corporation) Deleted 01/01/2026

VitaGraft™ Kidney Baseline + 1st Plasma Test (Oncocyte Corporation) Deleted 01/01/2026

VitaGraft™ Kidney Subsequent (Oncocyte Corporation) Deleted 01/01/2026

xT CDx (Tempus AI, Inc)

Proprietary Lab Tests Not Requiring Precertification

Providers should be aware that although the following tests do not require precertification, the codes listed in this section may not be covered for all lines of business. Coverage and benefit criteria still apply. For example; services ordered and or performed by out-of network providers may require precertification for certain plan types. Confirm coverage guidelines with CMS, BMS, or plan documents and The Health Plan.

Accelerate PhenoTest™ BC Kit (Accelerate Diagnostics) 0086U- May not be covered for all lines of business

AmHPR® H. pylori Antibiotic Resistance Panel (American Molecular Laboratories)

Bacterial Typing by Whole Genome Sequencing (Mayo Clinic)

BCR-ABL1 major and minor breakpoint fusion transcripts (University of Iowa, Department of Pathology, Asuragen)

BDX-XL2 (Biodesix®, Inc)

- Covered for individuals >40 yrs of age, and
- Pulmonary nodule of diameter 8-30mm, and
- Pre-test risk of cancer 50% or less.

BioPlex 2200 Syphilis Total & RPR Assay (Bio-Rad Laboratories), and

BioPlex 2200 RPR Assay (Bio-Rad Laboratories)

- Covered as a screening of all pregnant women, and persons who are at risk of syphilis infection.
- Diagnostic testing of individuals with signs and symptoms of syphilis.

BLOODchip® ID CORE XT™ (Grifols Diagnostic Solutions Inc)

- Covered Pre-transfusion molecular testing (red blood cells, platelets, or white blood cells) with one or all of the following,
- Longterm frequent transfusions anticipated and risk for developing antibodies,
- Autoantibodies or other serologic reactivity interferes with the exclusion of clinically significant alloantibodies,
- Suspected antibody against an antigen for which typing sera is not available,
- Laboratory discrepancies on serological typing,
- The individual has not previously been tested for blood cell antigen.

Cap-Score™ Test (Androvia Life Sciences)- Plans with infertility benefits may cover based on plan design. Those benefits may be limited to certain services only.

Catechol-O-Methyltransferase (COMT) genotype (Mayo Clinic)

CNGnome™ (PerkinElmer Genomics)

Cologuard Plus™ (Exact Science Laboratories, LLC, Exact Science Corporation) 0464U. As of 2/1/2025 .

Colvera® (Clinical Genomics Pathology Inc) -Currently only covered for Medicare plans

Cordant CORE™ (Cordant Health Solutions)

CustomNext +RNA: APC, MLH1, MSH2, MSH6, PMS2, Lynch (Ambry Genetics)

- Covered targeted multi-gene panel for hereditary colon cancer syndromes (APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53) that meet guidelines .

CYP2D6 Common Variants and Copy Number, Full Genome Sequencing, Hybrid Gene Targeted Sequence Analysis (2D6 and 2D7), Trans-duplication/gene duplication/multiplication tests. Codes 0070U--0076U (Mayo Clinic). Include any add on codes.

- Above tests are covered for members who have been prescribed doses of tetrabenazine (Xenazine) greater than 50 mg per day.
- Covered fo DX Gaucher disease type 1 who are being considered for treatment with eliglustat (Cerdelga).
- Covered for indications listed in Medicare LCD *MOLDX: Pharmacogenomics Testing (L38394)*
- Repeat CYP2D6 genotyping has no proven value and will not be reimbursed.

Cytochrome P450 1A2 Genotype (Mayo Clinic)

DEPArray™ HER2 (PacificDx)

DISCERN™ (NeuroDiagnostics) Codes 0206U and 0207U- Covered for Medicare plans only

Ektacytometry (BioChip Labs™)

- Covered for the diagnosis of red blood cell (RBC) cytoskeleton and hydration disorders (e.g., hereditary spherocytosis, pyro-poikilocytosis, stomatocytosis, ovalocytosis, elliptocytosis and xerocytosis) when RBC morphology does not provide a clear diagnosis.

ePlex Respiratory Pathogen (RP) Panel and ePlex Respiratory Pathogen Panel 2 (GenMark Diagnostics, Inc)

- Covered for the indications listed in Palmetto and CGS LCD's Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L38988 and L39038 and Article A58710 and A58747).

ePlex® BCID Fungal Pathogens Panel (GenMark Diagnostics, Inc)

ePlex® BCID Gram- Positive Panel (GenMark Diagnostics, Inc)

- Covered for the indications listed in Palmetto and CGS's LCD's Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L38988 and L39038 and Article A58710 and A58747).

ePlex® BCID Gram- Negative Panel (GenMark Diagnostics, Inc)

- Covered for the indications listed in Palmetto and CGS LCD's Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L38988 and L39038 and Article A58710and A58747).

ExosomeDX® Prostate (IntelliScore) (Exosome Diagnostics, Inc)

- Does not have established diagnosis of prostate cancer.
- Test ordered by physician specialist (e.g. urologist and oncologist) for treatment and management decision

FLT3 ITD MRD (NGS, Lab PMM LLC, an Invivoscribe Technologies, Inc Company)

Focused Pharmacogenomics Panel (Mayo Clinic)

FRAT® (Folate Receptor Antibody Test) (Religen Inc)

- Covered for evaluation of individuals with cerebral folate deficiency syndrome.

Genomic Unity® AR, CACNA1A, CSTB, FXN, MECP2, PTEN, and SMN1/2 Analysis Tests (Variantyx Inc)

Genomic Unity® Cardiac Ion Channelopathies Analysis and Lynch Syndrome Analysis Tests (Variantyx Inc)

HPV, High-Risk, Male Urine (Molecular Testing Labs)

HPV-SEQ Test (Sysmex Inostics, Inc)- Currently only covered for certain Medicare plans upon claim review.

JAK2 Mutation (University of Iowa, Department of Pathology)

JAK2 Exons 12 to 15 Sequencing (Mayo Clinic)

LeukoStrat®CDx FLT3 Mutation Assay (LabPMM LLC, an Invivoscribe Technologies, Inc Company)

Lumipulse® G β-Amyloid Ratio (1-42/1-40) Test (Fujirebio Diagnostics, Inc)

- Covered for individuals with a confirmed diagnosis of Alzheimer's disease for selecting therapy based on β-amyloid (Aβ) status and tau staging and in identifying individuals likely to benefit the most from anti-Aβ treatments.

Lyme ImmunoBlot IgG and IgM tests (IgeneX Inc, ID-FISH Technology Inc (ASR))

Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots IgM Test and IgG Test (IgeneX Inc, ID-FISH Technology Inc)

- Lyme ImmunoBlot and Tick-Borne Relapsing Fever tests are covered for determination of definitive Diagnosis of Lyme Disease to support initial IV antibiotic therapy.
- The CDC recommends a 2-test approach using a sensitive enzyme immunoassay (EIA) or IFA followed by a Western immunoblot. All specimens positive or equivocal by a sensitive EIA or IFA should be tested by a standardized Western immunoblot.
- The CDC states when Western immunoblot is used during the first 4 weeks of disease onset (early LD), both immunoglobulin M (IgM) and immunoglobulin G (IgG) procedures should be performed.
- Tests performed outside of recommended parameters will not be covered.

MicroGenDX qPCR & NGS For Infection (MicroGenDX)- Currently only covered for Medicare plans.

MRDx BCR-ABL test (MolecularMD)

Navigator ABO, Rh Blood Group NGS (Grifols Immunohematology Center) - Currently only covered for Medicare plans.

Navigator ABO, CO, CROM, DI, DO, FUT1, FUT2, FY, GE, GYPA, GYPB, IN, JK, JR, KEL, KLF1, and LU Sequencing tests (Grifols Immunohematology Center)

Navigator LW, RHD/CE, SC, XK, YT Sequencing Tests (Grifols Immunohematology Center)

NPM1 MRD by NGS (LabPMM LLC, an Invivoscribe Technologies, Inc Company)

Omnia™ SARSCoV-2 Antigen Test (Qorvo Biotechnologies)

Pigmented Lesion Assay (PLA) (DermTech)

POC (Products of Conception) (Igenomix® USA)

Praxis™ Extended RAS Panel (Illumina)

- Covered for recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer or breast and/or ovarian cancer based on coverage guidelines indicated in Medicare's National Coverage Determination on Next Gen Sequencing (90.2).
- Covered for prognostic and predictive testing in colorectal cancer when guidelines are met.

PrecisionBlood™ (San Diego Blood Bank)- Currently only covered for Medicare plans

PredictSURE IBD™ Test (KSL Diagnostics, PredictImmune Ltd)- Currently only covered for Medicare plans upon claims review

Psych HealthPGxPanel (RPRD Diagnostics)- May only be covered for Medicare plans upon claims review .

QIAstat-Dx Respiratory SARS coV-2 Panel (QIAGEN Sciences)

Real-time quaking-induced conversion for prior detection (RT-QuIC) (National Prion Disease Pathology Surveillance Center)

+RNAinsight™ for ATM, BRCA 1/2, CancerNext® ColoNext®, PALB2, ProstateNext®, (Ambry Genetics)
May not be covered for all lines of business. Confirm Coverage CMS, BMS or plan documents.

Serotonin Receptor Genotype (HTR2A and HTR 2 C) (Mayo Clinic)- Deleted 01/01/2026

Shield™(Guardant Health)

- Blood based biomarker test covered for colorectal screening for members at least 45 years of age and asymptomatic, and
- Initial test, or at least 3 years since last test.

Singulex Clarity C. diff toxins A/B assay (Singulex)

- Covered to detect the presence of Clostridium difficile toxins in a stool sample due to signs/symptoms C-difficile.

SMART PGT-A (Pre-implantation Genetic Testing- Aneuploidy) (Igenomix® USA)

Smart PGT-A Plus, Igenomix®, Smart PGT-SR, Igenomix®, and Smart PGT-SR Plus (Igenomix®, Part of Vitrolife Group™, Thermo Fisher Scientific)

- Covered for pre-implantation genetic diseases (PGD) if one or more biological parents has a known translocation in chromosome 13, 18, or 21
- Not covered for any other indication
- Support must be submitted with claim.

Therascreen® FGFR RGQ RT-PCR Kit (Qiagen)

Therascreen® PIK3CA RGQ RT-PCR Kit (Qiagen)

Therascreen® PIK3CA RGQ PCR Kit (Qiagen)

Thiopurine Methyltransferase (TPMT) and Nudix hydrolase (NUDT15) (Mayo Clinic)

ToxProtect (Genotx Laboratories)

- Billing unit limits may apply.
- Refer to Clinical Drug Testing in Addiction Treatment Programs and Pain Management Programs Policy.

Trimethylamine (TMA) and TMA N-Oxide (Children's Hospital Colorado Laboratories)

- Measurement of urinary trimethylamine (TMA) and TMA-N-oxide (TMAO) is considered medically necessary for diagnosing individuals with foul smelling urine suspected of having trimethylaminuria (fish odor syndrome).

Twins Zygosity PLA (Natera Inc)

Vita Risk® (Artic Medical Laboratories)- Currently only covered for Medicare plans.

VeriMap™ Peanut DX Bead-Based Epitope Assay (AllerGenis™ Clinical Clinical Laboratory, AllerGenis™, LLC)- Only covered for Medicare plans

VeriMap™ Peanut Reactivity Bead-Based Epitope Assay (AllerGenis™ Clinical Clinical Laboratory, AllerGenis™, LLC)- Only covered for Medicare plans

Warfarin Response Genotype (Mayo Clinic)

Not Currently Covered or Excluded:

FDA approval and/or clearance alone is not an indication of coverage. The following tests are considered experimental or investigational as of the release or update of this policy, there is insufficient evidence from current peer review literature or Medicare coverage guidelines to support the use of these tests. Not an all inclusive list.

Evidence does not support the use of comprehensive multi-gene panels for predictive or prognostic testing in CRC.

There is limited evidence to support the use of liquid biopsy testing for plasma cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) to predict recurrence of CRC or monitor response to CRC therapy in postoperative settings. Literature review of current evidence does not support the used of liquid biopsy testing in other clinical settings.

- **13C-Spirulina Gastric Emptying Breath Test (GEBT) (Cairn Diagnostics d/b/a Advanced Breath Diagnostics, LLC)**
- **3D Predict Glioma (KIYATEC®, Inc)**- Non-covered indications for chemosensitivity and chemoresistance assay.
- **3D Predict™ Ovarian (KIYATEC®, Inc)**
- **Accelerate PhenoTest® BC Kit, AST configuration (Accelerate Diagnostics, Inc) 0311U**
- **AChR Live Cell-Based Assay (Neurocode USA, Inc)**
- **AidaBreast™ (PreludeDx™ Prelude Corporation)**
- **aiSLE® DX Disease Activity Index (Progentec Diagnostics, Inc)**
- **aiSLE® DX Flare Risk Index (Progentec Diagnostics, Inc)**
- **ALICE (Analysis of Infectious Chronic Endometritis) (Igenomix® USA)**
- **ALZpath pTau217 (Neurocode USA, Inc, Quanterix/ALZpath)**
- **AMBLor® Melanoma Prognostic Test (Avero® Diagnostics)**
- **Amplified Sciences PanCystPro™ (Amplified Sciences, Inc)**

- **Anti-dsDNA, High Salt/Avidity (University of Washington, Department of Laboratory Medicine, Bio-Rad)**
- **Apifyn® (Armune BioScience, Inc)**
- **ArteraAI Prostate Test (Artera Inc®)**
- **AssureMDx™ (Vesica Health® Inc)**
- **AssuranceRx (Micro Serum, Firstox Laboratories, LLC)**
- **Auria® (Namida Lab, Inc)**
- **Aventa Lymphoma, (Aventa Genomics, LLC)**
- **Avantect Ovarian Cancer Test (Clear Note® Health)**
- **Avise® Lupus (Exagen, Inc)**
- **Bacteria, Viruses, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid (MSCSF) (Mayo Clinic Laboratory)**
- **BBDRiskDx™ (Silbiotech, Inc)**
- **Bescreened™-CRC (Beacon Biomedical Inc)**
- **BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel, (bioMérieux)**
- **BIOTIA-ID™ Urine NGS Assay, (Biotia, Inc)**
- **Bladder CARE™ (Pangea Laboratory, LLC)**
- **Bradykinin Quantitative (Virant Diagnostics)**
- **Branched-Chain Amino Acids, Self-Collect, Blood Spot (Mayo Clinic, Laboratory Developed Test)**
- **Bridge Urinary Tract Infection Detection and Resistance Test (Bridge Diagnostics)**
- **Bridge Women's Health Infectious Disease Detection Test (Bridge Diagnostics, Thermo Fisher and Hologic Test Kit on Panther Instrument)**
- **CareView360 (Newstar Medical Laboratories, LLC)**
- **CELLSEARCH® Circulating Melanoma Cell (CMC) Test (Menarini Silicon Biosystems, Inc)**
- **CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Test (Menarini Silicon Biosystems, Inc)**
- **CELLSEARCH® ER Circulating Tumor Cell (CTC-ER) Test (Menarini Silicon Biosystems, Inc)**
- **CELLSEARCH® PDL1 Circulating Tumor Cell (CTCPD-L1) Test (Menarini Silicon Biosystems, Inc)**
- **ChemID® (ChemID® Lab, Cordgenics, LLC)**
- **CHOP VEO-IBD Genetic Panel (Children's Hospital of Philadelphia) Possible CPT Codes (at this time 81404 x 2, 81405, 81406 x 4, 81479)**
- **Clarava™ (Verici Dx, Inc)**
- **ClarityDx Prostate (Protean BioDiagnostics) Deleted 01/01/2026 possibly being recoded 1/1/2026 as code 0609U with updated description change**
- **ColonAiQ (Breakthrough Genomics, Singlera Genomics, Inc)**
- **Coloscape™PLUS (DiCarta, Inc)**
- **Colosense™ (Geneoscopy, Inc)**
- **ComplyRX (Claro Labs)**
- **Covid-19 Antibody Test (Mt Sinai Laboratory)**
- **Cxbladder™ Triage (Pacific Edge Diagnostics USA, Ltd)- May be covered for Medicare members upon claim review**
- **Cxbladder Triage Plus ((Pacific Edge Diagnostics USA, Ltd)- May be covered for Medicare members**

upon claim review

- **CXCL10 Urine test (One Lambda™ Inc)**
- **CyPath® Lung (Precision Pathology Services, bioAffinity Technologies, Inc)**
- **DCISionRT® (PreludeDx™, Prelude Corporation)**
- **DecisionDx™ -SCC (Castle Biosciences, Inc)**
- **DiviTum®TKa (Biovica Inc)**
- **EarlyDx MethylScan™ HCC (EarlyDiagnostics Laboratory)**
- **Early Sepsis Indicator (Beckman Coulter Inc.)**
- **Early Sjören's Syndrom Profile (Immco Diagnostics, Inc)**
- **EarlyTect® Bladder Cancer Detection (EarlyTect® BCD), (Promis Diagnostics, Inc)**
- **EffectiveRX™ Comprehensive Panel (RCA laboratory Services LLC d/b/a GENETWORx)**
- **EMMA (Endometrial Microbiome Metagenomic Analysis), (Igenomix® USA)**
- **Endosign® Barrett's Esophagus Test (Cyted Health, Inc)**
- **Epignostix CNS Tumor Methylation Classifier (Heidelberg Epignostix GmbH)**
- **EPISEEK™ MPE (Malignant Pleural Effusion Detection Test) (Precision Epigenomics, Inc)**
- **EsoGuard™ (Lucid Diagnostics)**
- **Esophageal String Test™(EST) (EnteroTrack™ Labs, EnteroTrack, LLC)**
- **FebriDx® Bacterial/NonBacterial Point-of Care Assay (Lumos Diagnostics LLC)**
- **FidaLab Molecular Wound Infection Test (FidaLab LLC)**
- **FirstSightCRC™ (CellMax Life)**
- **Flow Adhesion of Whole Blood on VCAM-1 (FAB-V) (Functional Fluidics)**
- **Flow Adhesion of Whole Blood to P-SELECTIN (WB-PSEL) (Functional Fluidics)**
- **Foundation PI™ (Ethos Laboratories)**
- **GeneSight Analgesic, GeneSight MTHFR-Would use 81479 or 81291 respectively and may not be covered depending on reason for test and line of business.**
- **Glial Fibrillary Acidic Protein Blood Test (Neurocode USA, Inc) (Fujirebio Diagnostics, Inc)**
- **GFR by NMR (Labtech™ Diagnostics)**
- **GlycA (Laboratory Corporation of America)**
- **Glycine receptor alpha1 IgG, serum or cerebrospinal fluid(CSF), live cell-binding assay(LCBA), qualitative (Glycine Receptor Alpha1 IgG) (Mayo Clinic/Mayo Clinic Laboratories)**
- **GlycoKnow™ Ovarian (InterVenn Biosciences)**
- **Guardant Reveal™, Guardant Health, Inc- Code 0569U may be covered for Medicare plans upon claims review**
- **HART CADhs®, CVE®, and KD® Tests (Atlas Genomics, Prevencio, Inc)**
- **Haystack MRD™ Baseline (Quest Diagnostics®)**
- **Haystack MRD™ Monitoring (Quest Diagnostics®)**
- **HealthTrackRx Bronchitis (HealthTrackRx, Thermo Fisher Scientific)**
- **HealthTrackRx Vaginitis (HealthTrackRx, Thermo Fisher Scientific)**
- **HepatoTrack™ (LuminoDx Laboratory)**
- **HDL Reverse Cholesterol Transport Panel with pCAD Score (Quest Diagnostics®)**

- **HelioHCC™ Strat and HelioHCC™ Trace, (Helio Genomics®)**
- **HelioLiver™ Test (Fulgent Genetics, LLC, Helio Health, Inc)**- May be covered for Medicare plans upon claims review
- **Hypoxic BioChip Adhesion (BioChip Labs™)**
- **IBSchek® (Commonwealth Diagnostics International, Inc)**
- **ibs-smart™ (Germelli Biotech)**
- **IGoCheck™ (Blood-Based Colorectal Cancer Test) (Milagen, Inc)**
- **IVD CAPSULE PSP (Rapid Sepsis Test, Abionic SA)**
- **IMMray® PanCan-d (Immunovia, Inc)**
- **Immunoscore® (HalioDx)**
- **inFoods® IBS, (Ethos Laboratories)**
- **IntelliSep® Test, (Cytovale®)**
- **Intrinsic Hecpidin IDx™ Test (IntrinsicDx)**
- **IriSight CNV Analysis (Variantyx Inc)**
- **i-STAT TBI (Abbott Point of Care)**
- **Johns Hopkins Metagenomic Next- Generation Sequencing Assay for Infectious Disease Diagnostics (Johns Hopkins Medical Microbiology Laboratory)**
- **Kelch-Like Protein Screening Test (PSE) (Mayo Clinic)**
- **Diabetes Risk Test (Kihealth Inc®)**
- **Labcorp® Plasma Complete™ (Labcorp)**
- **LC-MS/MS Targeted Proteomic Assay (OncoOmicDX Laboratory, LDT)**
- **LifeScale Gram Negative Kit (LSGN) with Lifescale AST system, (Affinity Biosensors, LLC)**
- **Lyme Borrelia Nanotrap® Urine Antigen Test (Galaxy Diagnostics, Inc)**
- **Liposcale® (CIMA Sciences, LLC)**
- **LiverFAST™ (Fibronostics)**
- **LRP4 Cell-Based Assay (Neurocode USA, Inc)**
- **LucentAD™ Complete (Quanterix Corporation)**
- **LucentAD p-Tau 217 (Quanterix Corporation) Deleted 01/01/2026**
- **LungOI (Imagene)**
- **Malasorption Evaluation Panel (Mayo Clinic)**
- **MammoCheck™ (Blood-Based Breast Cancer Test) (Milagen, Inc)**
- **MCED Tests (multi-cancer early detection tests). Example: GRAIL Test (Galleri) Currently in review by Medicare. Not FDA approved. Current coding (81479, 81599). Cancerguard™ (Exact Science) MCED (multicancer detection test) under development- clinical trial and not FDA approved.**
- **Mechanical Fragility, RBC by shear stress profiling and spectral analysis (Functional Fluidics)**
- **MeMed BV® (MeMed Diagnostics, Ltd)**
- **Merlin™ Test (SkylineDx USA, Inc)**
- **MI-HEART Ceramides, Plasma (Mayo Clinic) - May be covered for Medicare plans depending on jurisdiction**
- **M-InSight Patient Definition Assay (Corgenix Clinical Laboratory) Being deleted as of 10/01/2025.**
- **M-inSight Patient Follow-Up Assessment (Corgenix Clinical Laboratory) Being deleted as of 01/01/**

2025.

- **Merkel Smt Oncoprotein Antibody Titer (University of Washington, Department of Laboratory Medicine)**
- **Merkel Virus VP1 Capsid Antibody (University of Washington, Department of Laboratory Medicine)**
- **MiCheck® Prostate (Minomic®, Inc)**
- **MindX One™ Blood Test - Anxiety (MindX Sciences)**
- **myOLARIS™-KTdx (Olaris®, Inc)**
- **NanoDetect-TB™ (NanoPin Technologies, Inc)**
- **NASHnext™ (NIS4TM) (Labcorp)**
- **NaviDKD™ Predictive Diagnostic Screening for Kidney Health (Journey Biosciences, Inc)**
- **Neurofilament Light Blood Test (Neurocode USA, Inc) (Fujirebio Diagnostics, Inc)**
- **Neurofilament Light Chain(Nfl), digital immunoassay (Neuromuscular Clinical Lab at Washington University in St Louis School of Medicine)- Code Deleted 1/1/2026**
- **Neurofilament Light Chain(Nfl), ultra-sensitive immunoassay (Neuromuscular Clinical Lab at Washington University in St Louis School of Medicine)**
- **NeXGen™ Fungal/AFB NGS Assay (Eurofins Viracor, LLC)**
- **Nodify CDT® (Biodesix, Inc)**
- **Normoxic BioChip Adhesion (BioChip Labs™)**
- **NPDX ASD ADM Panel I and ASD Panel III Tests (Stemina Biomarker Discovery, Inc d/b/a NeuroPointDX)**
- **NPDX ASD and Central Carbon Energy Metabolism (Stemina Biomarker Discovery, Inc)**
- **OmniGraf® (EurofinsTransplant Genomics, LLC)**
- **Omnipathology Oropharyngeal HPV PCR Test (OmniPathology Solutions)**
- **OncoAssure™ Prostate (DiCarta, Inc)**
- **Oncuria® Detect, Oncuria® Monitor and Oncuria® Predict tests (DiaCarta Clinical Lab, Diacarta, Inc)**
- **OptiSeq™ Colorectal Cancer NGS Panel (DiaCarta, Inc)**
- **OptiSeq™ Dual Cancer Panel Kit (DiaCarta, Inc)**
- **Onco4D™ (Animated Dynamics, Inc)**
- **OncobiotaLUNG (Micronoma™)**
- **Oral Oncolytic Assurance RX (Firstox Laboratories, LLC)**
- **Osmotic Gradient Ektacytometry (Cincinnati Children's Clinical Laboratories)**
- **OvaWatch™ (Aspira Women's Health™, Aspira Labs, Inc)**
- **OVERA® (OVA1 Next Generation) (Aspira Labs, Inc, Vermillion, Inc)**
- **OWLiver® (CIMA Sciences, LLC)**
- **PanGIA Prostate (Genetics Institute of America)**
- **PancreaSure™ (Immunovia, Inc)**
- **Paris (Tempus AI, Inc)**
- **PEPredictDx (OncoOmicsDx Laboratory, mProbe)**
- **PFAS, Panel 2-24 (Forever Chemicals, Quest Diagnostics)**
- **PFAS 9-Panel (Forever Chemicals)**

- **PFAS Testing & PFASure™ (National Medical Services, NMS Labs, Inc)**
- **PFAS Testing &PFASure® FT (National Medical Services, NMS Labs)**
- **PGDx elio™ plasma focus Dx (Personal Genome Diagnostics, Inc)**
- **Phenylalanine and Tyrosine, Self-Collect, Blood Spot (Mayo Clinic, Laboratory Developed Test)**
- **PIGF Preeclampsia Screen (PerkinElmer Genetics, Inc)**
- **Preeclampsia sFlt1/PIGF Ratio (PERA) (Mayo Clinic)**
- **PreciseDx™ Breast Biopsy Test (PreciseDx)**
- **PreciseDX™ Breast Cancer Test (PreciseDx)**
- **PrecisView® CNS (Phenomix Health inc™)**
- **PrecivityAD® and PrecivityAD2™® (C2N Diagnostics, LLC)**
- **Precivity-ApoE™ (C2N Diagnostics, LLC)**
- **PredicineATLAS™ Assay (Predicine Inc)**
- **PredicineCARE™ Assay (Predicine Inc)**
- **Prenatal Detect RhD (Devyser Genomic Laboratories)**
- **PreTRM® (Sera Prognostics, Inc®)**
- **Procise ADL™ (ProciseDx, Inc)**
- **Procise IFFX™ (ProciseDx, Inc)**
- **PolyDX™ (Atlantic Diagnostic Laboratories)**
- **PromarkerD (Sonic Reference Laboratory, Proteomics International Pty Ltd)**
- **Proofer 7HPVMRNA E6 & E7 Biomarker Test (Global Diagnostic Labs, LLC, PrecTect as a Mel-Mount Medical, Inc subsidiary)**
- **PROphet® NSCLC Test (OncoHost, Inc)**
- **Prospera™ (Natera™)**
- **ProsTAV® (Life Length S.L.)**
- **PROSTOX™ ultra (MiraDx, Inc)**
- **PurlSTSM (Tempus AI, Inc)**
- **QuantidNA™ Colorectal Cancer Triage Test (DiaCarta, Inc)**
- **REVEAL Lung Nodule Characterization (MagArray, Inc)**
- **Resolution ctDx Lung™ (Resolution Bioscience, Inc)**
- **RNA Salah Targeted Expression Panel (Moffitt Cancer Center Advanced Diagnostics Laboratory)**
- **SafeDrugs (Astraeus Lab, LLC)**
- **Sensieva™ Droplet 250H Vitamin D2/D3 Microvolume LC/MS Assay (Insource Diagnostics)**
- **Seronegative Rheumatoid Arthritis Panel (KSL Diagnostics-Beutner Laboratories Inc, KSL Diagnostics Inc)**
- **PreClara™ Ratio (sFlt-1/PIGF) (Thermo Fisher Scientific)**
- **Single Cell Prenatal Diagnosis (SCPD) Test (Luna Genetics, Inc)**
- **SLE-key® Rule Out (Veracis, Inc)**
- **SmartHealth Vascular Dx™ (Morningstar Laboratories, LLC, SmartHealth DX)**
- **Snapshot Oral Fluid Compliance (Ethos Laboratories)**
- **Spatial Frequency Domain Imaging (SFDI) (Modulated Imaging, Inc.)**

- **Stockholm3 (BioAgilytix Diagnostics)**
- **SAAmplify™ Test (Amprion Clinical Laboratory)**
- **SLL Comprehensive Drug Analysis (Soft Landing Labs)**
- **Synovasure® Comprehensive PJI test Panel with SYN Tuition™ (CD Laboratories Inc)**
- **SyncView® Pain (Phenomix Health™, Inc)**
- **SyncView® PainPlus (Phenomix Health™, Inc)**
- **SyncView® Rx (Phenomix Health™, Inc)**
- **Taq Array Card Urinary Tract Infection PCR Panel, (SoftCell Laboratories, LLC)**
- **Tempus p-MSI (Tempus AI, Inc)**
- **Tempus p-Prostate (Tempus AI, Inc)**
- **Theralink® Reverse Phase Protein Array (RPPA) (Theralink® Technologies, Inc)**
- **Tissue Specific Markers for Early Diagnosis of Sjogren's Disease (KSL Diagnostics Inc)**
- **TissueCypher® Barrett's Esophagus Assay (Ceranostics)**
- **TriVerity™ (Inflammatix™, Inc)**
- **Tryptase Gene Copy Number Analysis (Virant Diagnostics, Inc)**
- **Tru-Immune™ (Ethos Laboratories)**
- **Tyrosinemia Follow-Up Panel, Self-Collect, Blood Spot (Mayo Clinic, Laboratory Developed Test)**
- **UncomplIDx (Elite Medical Laboratory Solution LLC)**
- **UNITY Fetal Antigen™ NIPT (BillionToOne Laboratory, BillionToOne Inc)**
- **Unity Fetal Risk Screen™ (BillionToOne Laboratory, BillionToOne Inc)**
- **Urinary Tract Infection Testing (NxGen MDx LLC)**
- **UriFind® Urothelial Carcinoma Assay (DiCatra, Inc)**
- **UroAMP MRD (Convergent Genomics, Inc)**
- **UrSure Tenofovir Quantification Test: (Synergy Medical Laboratories) - Check for Medicare coverage**
- **Vaginal Infection Testing (NxGen MDx LLC)**
- **VAP Cholesterol Test, (VAP Diagnostics Laboratory, Inc)**
- **Very-Long Chain AcylCoA Dehydrogenase (VLCAD) Enzyme Activity (Children's Hospital Colorado Laboratory)**
- **Versiti™ Heparin-Induced Thrombocytopenia Evaluation-PEA, Versiti™ Diagnostic Laboratories**

CODING GUIDELINES:

This list of codes is not intended to be all-inclusive as the American Medical Association (AMA) and Centers for Medicare and Medicaid Services (CMS) update and release code information occur more frequently than The Health Plan policy updates. Codes that are not active on date of service may not be eligible for reimbursement.

| | | |
|-------|--|---|
| 0020M | Oncology (central nervous system), analysis of 30000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass | Epignostix CNS Tumor Methylation Classifier, Heidelberg Epignostix GmbH |
|-------|--|---|

| | | |
|-------|---|--|
| 0001U | Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported | PreciseType® HEA Test, Immucor, Inc |
| 0002U | Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps. | PolypDX™ , Atlantic Diagnostic Laboratories, LLC, Metabolomic Technologies, Inc |
| 0003U | Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 ii, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score Medicare requires providers to bill 81500 for ROMA™ Medicare requires providers to bill 81503 for OVA1® | Overa (OVA1 Next Generation), Aspira Labs, Inc, Vermillion, Inc |
| 0005U | Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score | ExosomeDx® Prostate (IntelliScore) , Exosome Diagnostics, Inc |
| 0007U | Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service | ToxProtect, Genotox Laboratories LTD |
| 0008U | Helicobacter pylori detection and antibiotic resistance, dna, 16s and 23s rna, gyra, pbp1, rdxa and rpro, next generation sequencing, formalin-fixed paraffin-embedded or fresh tissue, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline and rifabutin | AmHPR® H. pylori Antibiotic Resistance Panel, American Molecular Laboratories, Inc |
| 0009U | Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified | DEPArray™ HER2, PacificDx |
| 0010U | Infectious disease (bacterial), strain typing by whole genome sequencing, phylogeneticbased report of strain relatedness, per submitted isolate | Bacterial Typing by Whole Genome Sequencing, Mayo Clinic |
| 0011U | Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds | Cordant CORE™ , Cordant Health Solutions |

| | | |
|-------|---|--|
| | and metabolites | |
| 0016U | Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation | BCR-ABL1 major and minor breakpoint fusion transcripts , University of Iowa, Department of Pathology, Asuragen |
| 0017U | Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected | JAK2 Mutation, University of Iowa, Department of Pathology |
| 0018U | Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score | ThyraMIR™, Interpace Diagnostics |
| 0019U | Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents | OncoTarget/OncoTreat, Columbia University Department of Pathology and Cell Biology, Darwin Health |
| 0021U | Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTRBM11, CEP 164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score; | Apify®®, Armune BioScience, Inc |
| 0022U | Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider | OncoPrint™ Dx Target Test, Thermo Fisher Scientific |
| 0023U | Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or nondetection of FLT3 mutation and indication for or against the use of midostaurin | LeukoStrat®CDx FLT3 Mutation Assay, LabPMM LLC, an Invivoscribe Technologies, Inc Company, |
| 0024U | Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative | GlycA, Laboratory Corporation of America |
| 0025U | Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative | UrSure Tenofovir Quantification Test, Synergy Medical Laboratories, UrSure Inc |
| 0026U | Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of | Thyroseq Genomic Classifier, CBLPath, Inc, University of Pittsburgh Medical Center |

| | | |
|-------|--|---|
| | malignancy" or "Negative, low probability of malignancy") (For the Thyroseq Genomic Classifier, by CBL Path Inc.) | |
| 0027U | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15 | JAK2 Exons 12 to 15 Sequencing, Mayo Clinic |
| 0029U | Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLC01B1, VKORC1 and rs12777823) | Focused Pharmacogenomics Panel, Mayo Clinic |
| 0030U | Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823) | Warfarin Response Genotype, Mayo Clinic |
| 0031U | CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7) | Cytochrome P450 1A2 Genotype, Mayo Clinic |
| 0032U | COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant | Catechol-O- Methyltransferase (COMT) Genotype, Mayo Clinic |
| 0033U | HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.6142211T>C], HTR2C rs3813929 [c.- 759C>T] and rs1414334 [c.551-3008C>G]) | Serotonin Receptor Genotype (HTR2A and HTR 2C), Mayo Clinic Deleted 01/01/2026 |
| 0034U | TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism), gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5) | Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15), Mayo Clinic |
| 0035U | Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking induced conformational conversion, qualitative For additional PLA code with identical clinical descriptor, see 0584U. | Real-time quaking- induced conversion for prion detection (RT-QuIC), National Prion Disease Pathology Surveillance Center |
| 0036U | Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses | ExaCT-1 Whole Exome Testing, Lab of Oncology- Molecular Detection, Weill Cornell Medicine-Clinical Genomics Laboratory |
| 0037U | Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden | FoundationOne CDx™ (F1CDx), Foundation Medicine, Inc |

| | | |
|-------|---|--|
| 0038U | Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative | Sensieva™ Droplet 25OH Vitamin D2/ D3 Microvolume LC/MS Assay, InSource Diagnostics |
| 0039U | Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity | Anti-dsDNA, High Salt/ Avidity, University of Washington, Department of Laboratory Medicine, Bio-Rad |
| 0040U | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative | MRDx BCR-ABL Test, MolecularMD |
| 0041U | Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM | Lyme ImmunoBlot IgM, IgeneX Inc, ID-FISH Technology Inc (ASR) (Lyme ImmunoBlot IgM Strips Only) |
| 0042U | Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG | Lyme ImmunoBlot IgG, IgeneX Inc, ID-FISH Technology Inc (ASR) (Lyme ImmunoBlot IgG Strips Only) |
| 0043U | Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups by immunoblot, IgM | Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots IgM Test , IgeneX Inc, ID-FISH Technology Inc (Provides TBRF ImmunoBlot IgM Strips) |
| 0044U | Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups by immunoblot, IgG | Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots IgG Test, IgeneX Inc, ID-FISH Technology Inc (Provides TBRF ImmunoBlot IgG Strips) |
| 0045U | Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by realtime RTPCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score | The Oncotype DX® Breast DCIS Score™ Test, Genomic Health, Inc |
| 0046U | FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative | FLT3 ITD MRD by NGS, LabPMM LLC, an Invivoscribe Technologies, Inc Company |
| 0047U | Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score | Genomic Prostate Score® (GPS) Test, MDxHealth, Inc. |
| 0048U | Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) | MSK-IMPACT, Integrated Mutation Profiling of Actionable Cancer Targets, Memorial Sloan Kettering Cancer Center |

| | | |
|-------|--|--|
| 0049U | NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative | NPM1 MRD by NGS, LabPMM LLC, an Invivoscribe Technologies, Inc Company |
| 0050U | Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements | MyAML NGS Panel, LabPMM LLC, an Invivoscribe Technologies, Inc Company |
| 0051U | Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service | UcomplidX, Elite Medical Laboratory Solutions, LLC |
| 0052U | Measurement of all five major lipoprotein classes and subclasses in blood | VAP Cholesterol Test, VAP Diagnostics Laboratory, Inc |
| 0054U | Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service | AssuranceRx Micro Serum, Firstox Laboratories, LLC |
| 0055U | Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma | myTAIHEART, TAI Diagnostics, Inc |
| 0058U | Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative | Merkel SmT Oncoprotein Antibody Titer, University of Washington, Department of Laboratory Medicine |
| 0059U | Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative | Merkel Virus VP1 Capsid Antibody, University of Washington, Department of Laboratory Medicine |
| 0060U | Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood. Not covered as a screening tool in the general population | Twins Zygosity PLA, Natera, Inc |
| 0061U | Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin | Spatial Frequency Domain Imaging (SFDI) by Modulated Imaging, Inc. |
| 0062U | Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score | SLE-key® Rule Out, Veracis Inc |
| 0063U | Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder [metabolomic analysis of blood samples] | NPDX ASD ADM Panel I, Stemina Biomarker Discovery, Inc d/b/a NeuroPointDX |

| | | |
|--------|---|---|
| 0064U | Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative | BioPlex 2200 Syphilis Total & RPR Assay, Bio-Rad Laboratories |
| 0065U | Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR) | BioPlex 2200 RPR Assay, Bio-Rad Laboratories |
| 0067U | Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score | BBDRisk Dx™, Silbiotech, Inc |
| 0068U | Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species | MYCODART-PCR™ Dual Amplification Real Time PCR Panel for 6 Candida species, RealTime Laboratories, Inc/ MycoDART, Inc |
| 0069U | Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score | miR-31now™, GoPath Laboratories |
| 0070U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, 5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN) | CYP2D6 Common Variants and Copy Number, Mayo Clinic, Laboratory Developed Test |
| +0071U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure) Code first 0070U | CYP2D6 Full Gene Sequencing, Mayo Clinic, Laboratory Developed Test |
| +0072U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure) Code first 0070U | CYP2D6-2D7 Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test |
| +0073U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure) Code first 0070U | CYP2D7-2D6 Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test |

| | | |
|--------|--|--|
| +0074U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure) Code first 0070U | CYP2D6 trans- duplication/ multiplication nonduplicated gene targeted sequence analysis, Mayo Clinic, Laboratory Developed Test |
| +0075U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (List separately in addition to code for primary procedure) Code first 0070U | CYP2D6 5' gene duplication/ multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test |
| +0076U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/ multiplication) (List separately in addition to code for primary procedure) Code first 0070U | CYP2D6 3' gene duplication/ multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test |
| 0077U | Immunoglobulin paraprotein (m-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype | M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry, Mayo Clinic, Laboratory Developed Test |
| 0079U | Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (snps), urine and buccal DNA, for specimen identity verification | ToxLok™, InSource Diagnostics |
| 0080U | Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein m130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy | BDX-XL2, Biodesix®, Inc, |
| 0082U | Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service | Next Gen Precision™ Testing, Precision Diagnostics LBN Precision Toxicology, LLC |
| 0083U | Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combination | Onco4D™, Animated Dynamics, Inc |
| 0084U | Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 | BLOODchip® ID CORE XT™, Grifols Diagnostic Solutions Inc |

| | | |
|-------|---|---|
| | red blood cell antigens | |
| 0086U | Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility | Accelerate PhenoTest™ BC kit, Accelerate Diagnostics, Inc Do not confuse with CPT 0311U Accelerate PhenoTest® BC kit, AST configuration |
| 0087U | Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score | Molecular Microscope® MMDx-Heart, Kashi Clinical Laboratories |
| 0088U | Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection | Molecular Microscope® MMDx-Kidney, Kashi Clinical Laboratories |
| 0089U | Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) | Pigmented Lesion Assay DermTech Melanoma Test, DERM-JES Holdings, LLC d/b/a DermTech, LLC |
| 0090U | Oncology (cutaneous melanoma), MRNA gene expression profiling by rt-pcr of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) | myPath® Melanoma, Castle Biosciences, Inc |
| 0091U | Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result | FirstSightCRC™, CellMax Life |
| 0092U | Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy | REVEAL Lung Nodule Characterization, MagArray, Inc |
| 0093U | Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected | ComplyRX, Claro Labs |
| 0094U | Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis | RCIGM Rapid Whole Genome Sequencing, Rady Children's Institute for Genomic Medicine (RCIGM) Broad panel for 0425U |
| 0095U | Eosinophilic esophagitis, 2 protein biomarkers (Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and Major Basic Protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}]), enzyme-linked immunosorbent assays (ELISA), specimen obtained by | Esophageal String Test™ (EST), EnteroTrack™ Labs, EnteroTrack, LLC |

| | | |
|-------|---|---|
| | esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis | |
| 0096U | Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine | HPV, High-Risk, Male Urine, Molecular Testing Labs |
| 0101U | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only]) | ColoNext®, Ambry Genetics® |
| 0102U | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication]) | BreastNext®, Ambry Genetics® |
| 0103U | Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only]) | OvaNext®, Ambry Genetics® |
| 0105U | Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (eclia) of tumor necrosis factor receptor 1a, receptor superfamily 2 (tnfr1, tnfr2), and kidney injury molecule-1 (kim-1) combined with longitudinal clinical data, including apol1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (rkfd) | KidneyIntel (Renalytix Inc, NYC, NY) |
| 0106U | Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion | 13C-Spirulina Gastric Emptying Breath Test (GEBT), Cairn Diagnostics d/b/a Advanced Breath Diagnostics, LLC |

| | | |
|-------|---|--|
| 0107U | Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple- step method | Singulex Clarity C. diff toxins A/B assay, Singulex |
| 0108U | Gastroenterology (Barrett's esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53,CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer | TissueCypher® Barrett's Esophagus Assay, Ceranostics |
| 0109U | Infectious disease (aspergillus species), real-time pcr for detection of dna from 4 species (a. Fumigatus, a. Terreus, a. Niger, and a. Flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species | MYCODART- PCR™ Dual Amplification Real Time PCR Panel for 4 Aspergillus species, RealTime Laboratories, Inc/ MycoDART, Inc |
| 0110U | Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected | Oral OncolyticAssuranceRX, Firstox Laboratories, LLC |
| 0111U | Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue | Praxis™ Extended RAS Panel, Illumina |
| 0112U | Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene | MicroGenDX qPCR & NGS For Infection, MicroGenDX |
| 0113U | Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score | MyProstateScore, Lynx DX |
| 0114U | Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus | EsoGuard™, Lucid Diagnostics |
| 0115U | Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | ePlex Respiratory Pathogen (RP) Panel, GenMark Diagnostics, Inc |
| 0116U | Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of | Snapshot Oral Fluid Compliance, Ethos Laboratories |

| | | |
|-------|---|--|
| | drug to drug interactions for prescribed medications | |
| 0117U | Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain | Foundation PI SM , Ethos Laboratories |
| 0118U | Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA | Eurofins TRAC TM dd- cfDNA, Transplant Genomics Inc, |
| 0119U | Cardiology, ceramides by liquid chromatography–tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events | MI-HEART Ceramides, Plasma, Mayo Clinic, Laboratory Developed Test |
| 0120U | Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter | Lymph3Cx Lymphoma Molecular Subtyping Assay, Mayo Clinic, Laboratory Developed Test |
| 0121U | Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood | Flow Adhesion of Whole Blood on VCAM-1 (FAB-V), Functional Fluidics |
| 0122U | Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood | Flow Adhesion of Whole Blood to P-SELECTIN (WB-PSEL), Functional Fluidics |
| 0123U | Mechanical fragility, RBC, shear stress and spectral analysis profiling | Mechanical Fragility, RBC by shear stress profiling and spectral analysis, Functional Fluidics |
| 0129U | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53) | BRCPlus, Ambry Genetics |

| | | |
|--------|--|---|
| +0130U | Hereditary colon cancer disorders (eg, lynch syndrome, pten hamartoma syndrome, cowden syndrome, familial adenomatosis polyposis), targeted mrna sequence analysis panel (apc, cdh1, chek2, mlh1, msh2, msh6, mutyh, pms2, pten, and tp53) Code first 81435, 0101U | +RNAinsight™ for ColoNext®, Ambry Genetics |
| +0131U | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mrna sequence analysis panel (13 genes) (list separately in addition to code for primary procedure) Code first 81435, 0101U | RNAinsight™ for BreastNext®, Ambry Genetics Deleted as of 01/01/2026 |
| +0132U | Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure) Code first 81162, 81432, 0103U | RNAinsight™ for OvaNext®, Ambry Genetics Deleted as of 01/01/2026 |
| +0133U | Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure) Code first 81162 | RNAinsight™ for ProstateNext®, Ambry Genetics |
| +0134U | Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure) Code first 81162, 81432, 81435 | RNAinsight™ for CancerNext®, Ambry Genetics |
| +0135U | Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure) Code first 81162 | RNAinsight™ for GYNPlus®, Ambry Genetics Deleted 01/01/2026 |
| +0136U | ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81408 | RNAinsight™ for ATM, Ambry Genetics |

| | | |
|--------|--|--|
| +0137U | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81307 | RNAinsight™ for PALB2, Ambry Genetics |
| +0138U | BRCA1(BRCA1, DNA repair associated), BRCA2(BRCA2, DNA repair associated)(eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81162 | RNAinsight™ for BRCA1/2, Ambry Genetics |
| 0140U | Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected | ePlex® BCID Fungal Pathogens Panel, GenMark Diagnostics, Inc |
| 0141U | Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected | ePlex® BCID Gram- Positive Panel, GenMark Diagnostics, Inc |
| 0142U | Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected | ePlex® BCID Gram- Negative Panel, GenMark Diagnostics, Inc |
| 0152U | Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens | Karius® Test, Karius Inc |
| 0153U | Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement | Insight TNBCtype™, Insight Molecular Labs |
| 0154U | FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3TACC3v3) | therascreen® FGFR RGQ RT-PCR Kit, QIAGEN QIAGEN GmbH |
| 0155U | PIK3CA (phosphatidylinositol-4,5- bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, | therascreen® PIK3CA RGQ RT-PCR Kit, QIAGEN QIAGEN GmbH |

| | | |
|--------|---|--|
| | p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y) | |
| 0156U | Copy number (eg, intellectual disability, dysmorphology), sequence analysis | SMASH™ , New York Genome Center, Marvel Genomics™ |
| +0157U | APC (APC regulator of WNT signaling pathway) (eg, familial adenomatous polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81201 | CustomNext + RNA: APC, Ambry Genetics® |
| +0158U | MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81292 | CustomNext + RNA: MLH1, Ambry Genetics® |
| +0159U | MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81295 | CustomNext + RNA: MSH2, Ambry Genetics® |
| +0160U | MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81298 | CustomNext + RNA: MSH6, Ambry Genetics® |
| +0161U | PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary nonpolyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) Code first 81317 | CustomNext + RNA: PMS2, Ambry Genetics® |
| +0162U | Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure) Code first 81292, 81295, 81298, 81317, 81435 | CustomNext + RNA: Lynch (MLH1, MSH2, MSH6, PMS2), Ambry Genetics® |
| 0163U | Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of | BeScreened™-CRC, Beacon Biomedical Inc |

| | | |
|-------|--|---|
| | CRC or advanced adenomas | |
| 0164U | Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results | ibs-smart™, Gemelli Biotech |
| 0165U | Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope result and interpretation | VeriMAP™ Peanut Dx – Bead-based Epitope Assay, AllerGenis™ Clinical Laboratory, AllerGenis™ LLC |
| 0166U | Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation | LiverFASt™, Fibronostics |
| 0169U | NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants | NT (NUDT15 and TPMT) genotyping panel, RPRD Diagnostics |
| 0170U | Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/ absence | Clarifi™, Quadrant Biosciences, Inc |
| 0171U | Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/ absence | MyMRD® NGS Panel, Laboratory for Personalized Molecular Medicine |
| 0172U | Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score | myChoice® CDx, Myriad Genetics Laboratories, Inc |
| 0173U | Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes | Psych HealthPGx Panel, RPRD Diagnostics |

| | | |
|-------|--|--|
| 0174U | Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents | LC-MS/MS Targeted Proteomic Assay, OncoOmicDx Laboratory, LDT |
| 0175U | Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes | Genomind® Professional PGx Express™ CORE, Genomind, Inc |
| 0176U | Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (i.e., ELISA) | IBSchek®, Commonwealth Diagnostics International, Inc |
| 0177U | Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3- kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status | therascreen® PIK3CA RGQ PCR Kit, QIAGEN, QIAGEN GmbH |
| 0178U | Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction | VeriMAP™ Peanut Reactivity ThresholdBead Based Epitope Assay, AllerGenis™ Clinical Laboratory, AllerGenis™ LLC |
| 0179U | Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s) | Resolution ctDx Lung™, Resolution Bioscience, Inc |
| 0180U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons | Navigator ABO Sequencing, Grifols Immunoematology Center |
| 0181U | Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1 | Navigator CO Sequencing, Grifols Immunoematology Center |
| 0182U | Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10 | Navigator CROM Sequencing, Grifols Immunoematology Center |
| 0183U | Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19 | Navigator DI Sequencing, Grifols Immunoematology Center |
| 0184U | Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2 | Navigator DO Sequencing, Grifols Immunoematology Center |

| | | |
|-------|---|--|
| 0185U | Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4 | Navigator FUT1 Sequencing, Grifols Immunohematology Center |
| 0186U | Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2 | Navigator FUT2 Sequencing, Grifols Immunohematology Center |
| 0187U | Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2 | Navigator FY Sequencing, Grifols Immunohematology Center |
| 0188U | Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4 | Navigator GE Sequencing, Grifols Immunohematology Center |
| 0189U | Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2 | Navigator GYPA Sequencing, Grifols Immunohematology Center |
| 0190U | Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3 | Navigator GYPB Sequencing, Grifols Immunohematology Center |
| 0191U | Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6 | Navigator IN Sequencing, Grifols Immunohematology Center |
| 0192U | Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9 | Navigator JK Sequencing, Grifols Immunohematology Center |
| 0193U | Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26 | Navigator JR Sequencing, Grifols Immunohematology Center |
| 0194U | Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8 | Navigator KEL Sequencing, Grifols Immunohematology Center |
| 0195U | KLF1 (Kruppel-like factor 1), targeted sequencing (i.e., exon 13) | Navigator KLF1 Sequencing, Grifols Immunohematology Center |
| 0196U | Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3 | Navigator LU Sequencing, Grifols Immunohematology Center |
| 0197U | Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1 | Navigator LW Sequencing, Grifols Immunohematology Center |

| | | |
|--------|--|---|
| 0198U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5 | Navigator RHD/CE Sequencing, Grifols Immunohematology Center |
| 0199U | Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12 | Navigator SC Sequencing, Grifols Immunohematology Center |
| 0200U | Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3 | Navigator XK Sequencing, Grifols Immunohematology Center |
| 0201U | Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2 | Navigator YT Sequencing, Grifols Immunohematology Center |
| 0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected | BioFire® Respiratory Panel 2.1 (RP2.1), BioFire® Diagnostics, LLC |
| 0203U | Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory | PredictSURE IBD™ Test, KSL Diagnostics, PredictImmune Ltd |
| 0205U | Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age related macular-degeneration risk associated with zinc supplements | Vita Risk®, Arctic Medical Laboratories |
| 0206U | Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease | DISCERN™, NeuroDiagnostics |
| +0207U | Disease quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) Code first 0206U | DISCERN™, NeuroDiagnostics |

| | | |
|-------|---|---|
| 0209U | Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities | CNGnome™, PerkinElmer Genomics |
| 0210U | Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2 | BioPlex 2200 RPR Assay – Quantitative, Bio-Rad Laboratories |
| 0211U | Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association | MI Cancer Seek™ - NGS Analysis, Caris MPI d/b/a Caris Life Sciences |
| 0212U | Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband Excludes 81425 | Genomic Unity® Whole Genome Analysis – Proband, Variantyx Inc |
| 0213U | Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling) Excludes 81426 | Genomic Unity® Whole Genome Analysis – Comparator, Variantyx Inc |
| 0214U | Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband Excludes 81415 | Genomic Unity® Exome Plus Analysis – Proband, Variantyx Inc |
| 0215U | Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling) | Genomic Unity® Exome Plus Analysis – Comparator, Variantyx Inc |

| | | |
|-------|---|---|
| | Excludes 81416 | |
| 0216U | Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants | Genomic Unity® Ataxia Repeat Expansion and Sequence Analysis, Variantyx Inc |
| 0217U | Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants | Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence Analysis, Variantyx Inc |
| 0218U | Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants | Genomic Unity® DMD Analysis, Variantyx Inc |
| 0219U | Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (i.e., protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility | Sentosa ® SQ HIV-1 Genotyping Assay, Vela Operations Singapore Pte Ltd |
| 0220U | Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score | PreciseDX™, Breast Cancer Test, PreciseDx |
| 0221U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene | Navigator ABO Blood Group NGS, Grifols Immunohematology Center |
| 0222U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3 | Navigator Rh Blood Group NGS, Grifols Immunohematology Center |
| 0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected | QIAstat-Dx Respiratory SARS CoV-2 Panel, QIAGEN Sciences, QIAGEN GmbH |

| | | |
|-------|---|---|
| 0224U | Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed | COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory |
| 0225U | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | ePlex® Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc |
| 0226U | Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum | Tru-Immune™, Ethos Laboratories, GenScript® USA Inc |
| 0227U | Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation | Comprehensive Screen, Aspent Health |
| 0228U | Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer | PanGIA Prostate, Genetics Institute of America, Entopsis, LLC |
| 0229U | BCAT1 (Branched chain amino acid transaminase 1) or IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis | Colvera®, Clinical Genomics Pathology Inc |
| 0230U | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® AR Analysis, Variantyx Inc |
| 0231U | CACNA1A (calcium voltage-gated channel subunit alpha 1A) (eg, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® CACNA1A Analysis, Variantyx Inc |
| 0232U | CSTB (cystatin B) (eg, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) | Genomic Unity® CSTB Analysis, Variantyx Inc |

| | | |
|-------|---|--|
| | expansions, mobile element insertions, and variants in non-uniquely mappable regions | |
| 0233U | FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® FXN Analysis, Variantyx Inc |
| 0234U | MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® MECP2 Analysis, Variantyx Inc |
| 0235U | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® PTEN Analysis, Variantyx Inc |
| 0236U | SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2, centromeric) (eg, spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions | Genomic Unity® SMN1/2 Analysis, Variantyx Inc |
| 0237U | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® Cardiac Ion Channelopathies Analysis, Variantyx Inc |
| 0238U | Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions | Genomic Unity® Lynch Syndrome Analysis, Variantyx Inc |
| 0239U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations | FoundationOne® Liquid CDx, Foundation Medicine, Inc |

| | | |
|-------|--|---|
| 0242U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements | Guardant360® CDx, Guardant Health Inc |
| 0243U | Time-resolved fluorescence immunoassay of placental-growth factor in maternal serum to evaluate risk of preeclampsia | PIGF Preeclampsia Screen, PerkinElmer Genetics, Inc |
| 0244U | Gene analysis of 257 genes associated with solid organ cancer in tumor tissue sample, comprehensive genomic profiling | Oncotype MAP™ Pan-Cancer Tissue Test, Paradigm Diagnostics, Inc |
| 0245U | Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage | ThyGeNEXT® Thyroid Oncogene Panel, Interpace Diagnostics |
| 0246U | Red blood cell antigen typing, DNA, genotyping for 16 or more blood groups with phenotype prediction of 51 or more red blood cell antigens | PrecisionBlood™ , San Diego Blood Bank |
| 0247U | Quantitative measurement of insulin-like growth factor-binding protein 4 and sex hormone-binding globulin (SHBG) in maternal serum by LC-MS/MS to evaluate risk of premature birth | PreTRM®, Sera Prognostics, Inc® |
| 0248U | Oncology, spheroid cell culture in a 3D microenvironment, 12 drug panel, brain- or brain metastasis-response prediction for each drug | 3D Predict Glioma, KIYATEC®, Inc |
| 0249U | Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report | Theralink® Reverse Phase Protein Array (RPPA), Theralink® Technologies, Inc |
| 0250U | Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden | PGDx elio™ tissue complete, Personal Genome Diagnostics, Inc |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma | Intrinsic Hepcidin IDx™ Test, IntrinsicDx, Intrinsic LifeSciences™ LLC |
| 0252U | Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy | POC (Products of Conception), Igenomix® USA |

| | | |
|-------|---|--|
| 0253U | Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive) | ERA® (Endometrial Receptivity Analysis), Igenomix® USA |
| 0254U | Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested | SMART PGT-A (Pre-implantation Genetic Testing – Aneuploidy), Igenomix® USA |
| 0255U | Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score | Cap-Score™ Test, Androvia LifeSciences, Avantor Clinical Services (previously known as Therapak) |
| 0256U | Trimethylamine/trimethylamine N-oxide (TMA/TMAO) profile, tandem mass spectrometry (MS/MS), urine, with algorithmic analysis and interpretive report | Trimethylamine (TMA) and TMA N-Oxide, Children's Hospital Colorado Laboratory |
| 0257U | Very long chain acyl-coenzyme A (CoA) dehydrogenase (VLCAD), leukocyte enzyme activity, whole blood | Very-Long Chain AcylCoA Dehydrogenase (VLCAD) Enzyme Activity, Children's Hospital Colorado Laboratory |
| 0258U | Autoimmune (psoriasis), mRNA, next generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics | Mind.Px, Mindera Corporation |
| 0259U | Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative | GFR by NMR, Labtech™ Diagnostics |
| 0260U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping *Has an identical descriptor | Augusta Optical Genome Mapping, Georgia Esoteric and Molecular (GEM) Laboratory, LLC, Bionano Genomics Inc |

| | | |
|-------|--|---|
| 0261U | Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score | Immunoscore®, HalioDx |
| 0262U | Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin embedded (FFPE), algorithm reported as gene pathway activity score | OncoSignal 7 Pathway Signal, Protean BioDiagnostics, Philips Electronics Nederland BV |
| 0263U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, α -ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LCMS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD) | NPDX ASD and Central Carbon Energy Metabolism, Stemina Biomarker Discovery, Inc |
| 0264U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping. *Has an identical descriptor | Praxis Optical Genome Mapping, Praxis Genomics LLC |
| 0265U | Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants | Praxis Whole Genome Sequencing, Praxis Genomics LLC |
| 0266U | Unexplained constitutional or other heritable disorders or syndromes, tissue specific gene expression by whole transcriptome and next-generation sequencing, blood, formalin-fixed paraffin embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes | Praxis Transcriptome, Praxis Genomics LLC |
| 0267U | Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing | Praxis Combined Whole Genome Sequencing and Optical Genome Mapping, Praxis Genomics LLC |
| 0268U | Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid | Versiti™ aHUS Genetic Evaluation, Versiti™ Diagnostic Laboratories, Versiti™ |

| | | |
|-------|---|---|
| 0269U | Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 22 genes, blood, buccal swab, or amniotic fluid | Versiti™ Autosomal Dominant Thrombocytopenia Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0270U | Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid | Versiti™ Coagulation Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0271U | Hematology (congenital neutropenia), genomic sequence analysis of 24 genes, blood, buccal swab, or amniotic fluid | Versiti™ Congenital Neutropenia Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0272U | Hematology (genetic bleeding disorders), genomic sequence analysis of 60 genes and duplications/deletion of <i>PLAU</i> , blood, buccal swab, or amniotic fluid, comprehensive | Versiti™ Comprehensive Bleeding Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0273U | Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes (<i>F13A1</i> , <i>F13B</i> , <i>FGA</i> , <i>FGB</i> , <i>FGG</i> , <i>SERPINA1</i> , <i>SERPINE1</i> , <i>SERPINF2</i> , <i>PLAU</i>), blood, buccal swab, or amniotic fluid | Versiti™ Fibrinolytic Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0274U | Hematology (genetic platelet disorders), genomic sequence analysis of 62 genes and duplication /deletion of <i>PLAU</i> , blood, buccal swab, or amniotic fluid | Versiti™ Comprehensive Platelet Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0275U | Hematology (heparin-induced thrombocytopenia), platelet antibody reactivity by flow cytometry, serum | Versiti™ Heparin- Induced Thrombocytopenia Evaluation – PEA, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0276U | Hematology (inherited thrombocytopenia), genomic sequence analysis of 42 genes, blood, buccal swab, or amniotic fluid | Versiti™ Inherited Thrombocytopenia Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0277U | Hematology (genetic platelet function disorder), genomic sequence analysis of 40 genes and duplication/detection of <i>PLAU</i> , blood, buccal swab, or amniotic fluid | Versiti Platelet Function Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0278U | Hematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid | Versiti™ Thrombosis Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0279U | Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding | Versiti™ VWF Collagen III Binding, Versiti™ Diagnostic Laboratories, Versiti™ |

| | | |
|-------|---|---|
| 0280U | Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding | Versiti™ VWF Collagen IV Binding, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0281U | Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays (ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level | Versiti™ VWF Propeptide Antigen, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0282U | Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes | Versiti™ Red Cell Genotyping Panel, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0283U | von Willebrand factor (VWF), type 2B, platelet-binding evaluation, radioimmunoassay, plasma | Versiti™ VWD Type 2B Evaluation, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0284U | von Willebrand factor (VWF), type 2N, factor VIII and VWF binding evaluation, enzyme linked immunosorbent assays (ELISA), plasma | Versiti™ VWF Type 2N Binding, Versiti™ Diagnostic Laboratories, Versiti™ |
| 0285U | Oncology, disease progression and response monitoring to radiation, chemotherapy, or other systematic cancer treatments, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported in ng/mL | RadTox™ cfDNA test, DiaCarta Clinical Lab, DiaCarta Inc |
| 0286U | CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants | CNT (CEP72, TPMT and NUDT15) genotyping panel, RPRD Diagnostics |
| 0287U | Oncology (thyroid), DNA and mRNA, nextgeneration sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) | ThyroSeq® CRC, CBLPath, Inc, University of Pittsburgh Medical Center |
| 0288U | Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score | RiskReveal™, Razor Genomics |
| 0289U | Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score | MindX Blood Test™ Memory/Alzheimer's, MindX Sciences™ Laboratory, MindX Sciences™ Inc |

| | | |
|-------|--|--|
| 0290U | Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score | MindX Blood Test™ - Pain, MindX Sciences™ Laboratory, MindX Sciences™ Inc |
| 0291U | Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score | MindX Blood Test™ - Mood, MindX Sciences™ Laboratory, MindX Sciences™ Inc |
| 0292U | Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score | MindX Blood Test™ - Stress, MindX Sciences™ Laboratory, MindX Sciences™ Inc |
| 0293U | Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score | MindX Blood Test™ - Suicidality, MindX Sciences™ Laboratory, MindX Sciences™ Inc |
| 0294U | Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score | MindX Blood Test™ - Longevity, MindX Sciences™ Laboratory, MindX Sciences™ In |
| 0295U | Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score | DCISionRT®, PreludeDx™, Prelude Corporation |
| 0296U | Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy | mRNA CancerDetect™, Viome Life Sciences, Inc |
| 0297U | Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification | Praxis Somatic Whole Genome Sequencing, Praxis Genomics LLC |
| 0298U | Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification | Praxis Somatic Transcriptome, Praxis Genomics LLC |
| 0299U | Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant | Praxis Somatic Optical Genome Mapping, Praxis Genomics LLC |

| | | |
|-------|---|---|
| | identification | |
| 0300U | Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification | Praxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping, Praxis Genomics LLC |
| 0301U | Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR) | Bartonella ddPCR, Galaxy Diagnostics, Inc |
| 0302U | Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR) following liquid enrichment | Bartonella Digital ePCR™, Galaxy Diagnostics, Inc |
| 0303U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic | Hypoxic BioChip Adhesion, BioChip Labs™ |
| 0304U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic | Normoxic BioChip Adhesion, BioChip Labs™ |
| 0305U | Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index | Ektacytometry, BioChip Labs™ |
| 0306U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD | Invitae PCM Tissue Profiling and MRD Baseline Assay, Invitae Corporation |
| 0307U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD | Invitae PCM MRD Monitoring, Invitae Corporation |
| 0308U | Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD | HART CADhs®, Complete Omics, Inc, Prevencio, Inc |

| | | |
|-------|--|---|
| 0309U | Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event | HART CVE®, Complete Omics, Prevencio, Inc |
| 0310U | Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NTproBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD | HART KD®, Complete Omics, Prevencio, Inc |
| 0311U | Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organ identified | Accelerate PhenoTest® BC kit, AST configuration, Accelerate Diagnostics, Inc Do not confuse with CPT code 0086U. |
| 0312U | Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment | Avise® Lupus, Exagen Inc |
| 0313U | Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia) | PancreaSeq® Genomic Classifier, Molecular and Genomic Pathology Laboratory, University of Pittsburgh Medical Center |
| 0314U | Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) | DecisionDx® DiffDx™-Melanoma, Castle Biosciences, Inc |
| 0315U | Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B) | DecisionDx®-SCC, Castle Biosciences, Inc |
| 0316U | Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine | Lyme Borrelia Nanotrap® Urine Antigen Test, Galaxy Diagnostics Inc |
| 0317U | Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer | LungLB®, LungLife AI® |

| | | |
|-------|--|--|
| 0318U | Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood | EpiSign Complete, Greenwood Genetic Center |
| 0319U | Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection | Clarava™, Verici Dx, Verici Dx, Inc |
| 0320U | Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using post transplant peripheral blood, algorithm reported as a risk score for acute cellular rejection | Tuteva™, Verici Dx, Verici Dx, Inc |
| 0321U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique. | Bridge Urinary Tract Infection Detection and Resistance Test, Bridge Diagnostics |
| 0322U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD | NPDX ASD Test Panel III, Stemina Biomarker Discovery d/b/a NeuroPointDX |
| 0323U | Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi | Johns Hopkins Metagenomic Next-Generation Sequencing Assay for Infectious Disease Diagnostics, Johns Hopkins Medical Microbiology Laboratory |
| 0326U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden | Guardant360®, Guardant Health, Inc |
| 0327U | Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed | Vasistera™, Natera, Inc |
| 0328U | Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service | CareView360, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC |

| | | |
|-------|--|---|
| 0329U | Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, icosatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations | Oncomap™ ExTra, Exact Sciences, Inc, Genomic Health Inc |
| 0330U | Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab | Bridge Women's Health Infectious Disease Detection Test, Bridge Diagnostics, Thermo Fisher and Hologic Test Kit on Panther Instrument |
| 0331U | Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant | Augusta Hematology Optical Genome Mapping, Georgia Esoteric and Molecular Labs, Augusta University, Bionano |
| 0332U | Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy | EpiSwitch® CiRT (Checkpoint-inhibitor Response Test), Next Bio-Research Services, LLC, Oxford BioDynamics, PLC |
| 0333U | Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high- risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result | HelioLiver™ Test, Helio Genomics® |
| 0334U | Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin- embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden | Guardant360 Tissue Next™, Guardant Health, Inc |
| 0335U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants | IriSight™ Prenatal Analysis – Proband, Variantyx, Inc |

| | | |
|-------|--|---|
| 0336U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent) | IriSight™ Prenatal Analysis – Comparator, Variantyx, Inc |
| 0337U | Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood | CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Test, Menarini Silicon Biosystems, Inc |
| 0338U | Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker expressing cells, peripheral blood | CELLSEARCH® HER2 Circulating Tumor Cell (CTC- HER2) Test, Menarini Silicon Biosystems, Inc |
| 0339U | Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer | SelectMDx® for Prostate Cancer, MDxHealth®, Inc |
| 0340U | Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate | Signatera™, Natera, Inc |
| 0341U | Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid | Single Cell Prenatal Diagnosis (SCPD) Test, Luna Genetics, Inc |
| 0342U | Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline | IMMray® PanCan-d, Immunovia, Inc |

| | | |
|-------|--|--|
| 0343U | Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer | miR Sentinel™ Prostate Cancer Test, miR Scientific, LLC |
| 0344U | Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis | OWLiver®, CIMA Sciences, LLC |
| 0345U | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 | GeneSight® Psychotropic, Assurex Health, Inc, Myriad Genetics, Inc |
| 0347U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes | RightMed® PGx16 Test, OneOme®, LLC |
| 0348U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes | RightMed® Comprehensive Test Exclude F2 and F5, OneOme®, LLC |
| 0349U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions | RightMed® Comprehensive Test, OneOme®, LLC |
| 0350U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes | RightMed® Gene Report, OneOme®, LLC |
| 0351U | Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection | MeMed BV®, MeMed Diagnostics, Ltd |
| 0355U | APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2) | Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping, Quest Diagnostics® |
| 0356U | Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence | NavDx®, Naveris, Inc |

| | | |
|-------|---|---|
| 0358U | Neurology (mild cognitive impairment), analysis of B-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative | Lumipulse® G β-Amyloid Ratio (1-42/1-40) Test, Fujirebio Diagnostics, Inc |
| 0359U | Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer | IsoPSA®, Cleveland Diagnostics, Inc |
| 0360U | Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy | Nodify CDT®, Biodesix, Inc |
| 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative | Neurofilament Light Chain (NfL), Mayo Clinic Deleted 01/01/2026 |
| 0362U | Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture–enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes | Thyroid GuidePx®, Protean BioDiagnostics, Qualisure Diagnostics |
| 0363U | Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma | Cxbladder™ Triage, Pacific Edge Diagnostics USA, Ltd |
| 0364U | Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate | clonoSEQ® Assay , Adaptive Biotechnologies |
| 0365U | Oncology (bladder), 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA), by immunoassays, urine, diagnostic algorithm, including patients age, race, and gender, reported as a probability of harboring urothelial cancer | Oncuria® Detect, DiaCarta Clinical Lab, DiaCarta, Inc |
| 0366U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer | Oncuria® Monitor, DiaCarta Clinical Lab, DiaCarta, Inc |

| | | |
|-------|---|---|
| 0367U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection | Oncuria® Predict, DiaCarta Clinical Lab, DiaCarta, Inc |
| 0368U | Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer | ColoScape™ Colorectal Cancer Detection, DiaCarta Clinical Lab, DiaCarta, Inc |
| 0371U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine | Qlear UTI, Lifescan Labs of Illinois, Thermo Fisher Scientific |
| 0372U | Infectious disease (genitourinary detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score | Qlear UTI – Reflex ABR, Lifescan Labs of Illinois, Thermo Fisher Scientific |
| 0375U | Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [i.e., transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score | OvaWatch SM , Aspira Women's Health SM , Aspira Labs, Inc |
| 0376U | Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation- therapy response, if appropriate | ArteraAI Prostate Test, Artera Inc® |
| 0377U | Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables) | Liposcale®, CIMA Sciences, LLC |
| 0378U | RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat -primed PCR, blood, saliva, or buccal swab | UCGSL RFC1 Repeat Expansion Test, University of Chicago Genetic Services Laboratories |

| | | |
|-------|---|---|
| 0379U | Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden | Solid Tumor Expanded Panel, Quest Diagnostics® |
| 0381U | Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry(LC-MS/MS) | Branched-Chain Amino Acids, Self-Collect, Blood Spot, Mayo Clinic, Laboratory Developed Test |
| 0382U | Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) | Phenylalanine and Tyrosine, Self-Collect, Blood Spot, Mayo Clinic, Laboratory Developed Test |
| 0383U | Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry | Tyrosinemia Follow-Up Panel, Self-Collect, Blood Spot, Mayo Clinic, Laboratory Developed Test |
| 0384U | Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease | NaviDKD™ Predictive Diagnostic Screening for Kidney Health, Journey Biosciences, Inc |
| 0385U | Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease | PromarkerD, Sonic Reference Laboratory, Proteomics International Pty Ltd |
| 0387U | Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression | AMBLor® melanoma prognostic test, Avero® Diagnostics |
| 0388U | Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection | InVisionFirst®-Lung Liquid Biopsy, Inivata, Inc |

| | | |
|-------|---|--|
| 0389U | Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD | KawasakiDx, OncoOmicsDx Laboratory, mProbe |
| 0390U | Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score | PEPredictDx, OncoOmicsDx Laboratory, mProbe |
| 0391U | Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice-site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score | Strata Select™, Strata Oncology, Inc |
| 0392U | Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug | Medication Management Neuropsychiatric Panel, RCA Laboratory Services LLC d/b/a GENETWORx, GENETWORx |
| 0393U | Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded α -synuclein protein by seed amplification assay, qualitative | SAAmplify™-aSYNT, Amprion® Clinical Laboratory |
| 0394U | Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 PFAS compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative | PFAS Testing & PFASure™, National Medical Services, NMS Labs, Inc |
| 0395U | Oncology (lung), multi-omics (microbial DNA by shotgun next generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease | OncobiotaLUNG, Micronoma™ |
| 0398U | Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer | ESOPREDICT® Barrett's Esophagus Risk Classifier Assay, Capsulomics, Inc d/b/a Previs |

| | | |
|-------|---|---|
| 0399U | Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected | FRAT® (Folate Receptor Antibody Test, Religen Inc |
| 0400U | Obstetrics (expanded carrier screening), 145 genes by next-generation sequencing, fragment analysis and multiplex ligation-dependent probe amplification, DNA, reported as carrier positive or negative | Genesys Carrier Panel, Genesys Diagnostics, Inc |
| 0401U | Cardiology (coronary heart disease [CAD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event | CARDIO inCode-Score (CIC-SCORE), GENinCode U.S. Inc |
| 0402U | Infectious agent (sexually transmitted infection) Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected | Abbott Alinity™ m STI Assay, Abbott Molecular, Inc CT/NG/TV/MG |
| 0403U | Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer | MyProstateScore 2.0, LynxDX |
| 0404U | Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression | DiviTum®TKa, Biovica Inc, Biovica International AB |
| 0405U | Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected | BTG Early Detection of Pancreatic Cancer, Breakthrough Genomics providence NC |
| 0406U | Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer | CyPath® Lung, Precision Pathology Services, bioAffinity Technologies, Inc |
| 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function | KidneyintelX.dkd™, Renalytix Inc, NYC, NY |

| | | |
|-------|---|--|
| 0408U | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrode | Omnia™ SARSCoV-2 Antigen Test, Qorvo Biotechnologies, |
| 0409U | Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability | LiquidHALLMARK®, Lucence Health, Inc Analyzes circulating cell-free DNA and RNA from plasma specimens. This is not 0530U. |
| 0410U | Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected | Avantect™ Pancreatic Cancer Test, ClearNote™ Health |
| 0411U | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 | IDgenetix®, Castle Biosciences, Inc |
| 0412U | Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology | PrecisionAD® blood test, C2N Diagnostics LLC |
| 0413U | Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations | DH Optical Genome Mapping/Digital Karyotyping Assay, The Clinical Genomics and Advanced Technology (CGAT) Laboratory at Dartmouth Health, Bionano Genomics |
| 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin- embedded (FFPE) tissue, reported as positive or negative for each biomarker | LungOI, Imagen |

| | | |
|-------|---|--|
| 0415U | Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS [SmartVascular Dx] | SmartHealth Vascular Dx™, Morningstar Laboratories, LLC, SmartHealth DX |
| 0417U | Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder–associated genetic variants | Genomic Unity® Comprehensive Mitochondrial Disorders Analysis, Variantyx Inc |
| 0418U | Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score | PreciseDx Breast Biopsy Test, PreciseDx, Inc NYC,NY |
| 0419U | Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype | Tempus nP, Tempus Labs, Inc |
| 0420U | Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) of genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma | Cxbladder Triage Plus, Pacific Edge Diagnostics USA LTD |
| 0421U | Oncology(colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, EGLN2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk | Colosense™, Geneoscopy, Inc |
| 0422U | Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre- | Guardant 360 Response™, Guardant Health, Inc |

| | | |
|--------|--|--|
| | treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate | |
| 0423U | Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition | Genomind® Pharmacogenetics Report – Full, Genomind®, Inc |
| 0424U | Oncology (prostate), exosome- based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RTqPCR), urine, reported as no molecular evidence, low-,moderate-, or elevated-risk of prostate cancer | miR Sentinel™ Prostate Cancer Test, miR Scientific®, LLC |
| 0425U | Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings) | RCIGM Rapid Whole Genome Sequencing, Comparator Genome, Rady Children's Institute for Genomic Medicine |
| 0426U | Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis | RCIGM Ultra-Rapid Whole Genome Sequencing, Rady Children's Institute for Genomic Medicine |
| +0427U | Monocyte distribution width, whole blood (List separately in addition to code for primary procedure). (Use 0427U in conjunction with 85004, 85025) | Early Sepsis Indicator, Beckman Coulter, Inc |
| 0429U | Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) Use G0476 (Cervical cancer screening, all-inclusive HPV co-test with cytology (Pap smear) allowed once every 5 years . Females ages 30-65 years. | Omnipathology Oropharyngeal HPV PCR Test, OmniPathology Solutions, Medical Corporation |
| 0430U | Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative | Malabsorption Evaluation Panel, Mayo Clinic/Mayo Clinic Laboratories, Mayo Clinic |
| 0431U | Glycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell-binding assay (LCBA), qualitative | Glycine Receptor Alpha1 IgG, Mayo Clinic/Mayo Clinic Laboratories |

| | | |
|-------|--|--|
| 0432U | Kelch-like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative | Kelch-Like Protein 11 Antibody, Mayo Clinic/Mayo Clinic Laboratories, Mayo Clinic |
| 0433U | Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer | EpiSwitch® Prostate Screening Test (PSE), Oxford BioDynamics Inc, Oxford BioDynamics PLC |
| 0434U | Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes | RightMed® Gene Test Exclude F2 and F5, OneOme® LLC |
| 0435U | Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations | ChemoID®, ChemoID® Lab, Cordgenics, LLC |
| 0436U | Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy | PROphet® NSCLC Test, OncoHost, Inc |
| 0437U | Psychiatry(anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers,whole blood, algorithm reported as predictive risk score | MindX One™ Blood Test – Anxiety, MindX Sciences |
| 0438U | Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions | EffectiveRX™ Comprehensive Panel, RCA Laboratory Services LLC d/b/a d/b/a GENETWORx |
| 0439U | Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD | Epi+Gen CHD™, Cardio Diagnostics, Inc |

| | | |
|-------|---|---|
| 0440U | Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1], cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD | PrecisionCHD™, Cardio Diagnostics, Inc |
| 0441U | Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index | IntelliSep® Test, Cytovale® |
| 0442U | Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent | FebriDx® Bacterial/NonBacterial Point-of Care Assay, Lumos Diagnostics, LLC |
| 0443U | Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid | Neurofilament Light Chain (NfL), Neuromuscular Clinical Laboratory at Washington University in St. Louis School of Medicine |
| 0444U | Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-hyphenfixed paraffin-hyphenembedded (FFPE) tumor tissue, report of clinically significant variant(s) | Aventa FusionPlus™, Aventa Genomics, LLC |
| 0445U | β-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology | Elecsys® PhosphoTau (181P) CSF (pTau181) and βAmyloid (1-42) CSF II (Abeta 42) Ratio, Roche Diagnostics Operations, Inc (US owner/operator) |

| | | |
|-------|---|---|
| 0446U | Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity | aisle® DX Disease Activity Index, Progentec Diagnostics, Inc |
| 0447U | Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare | aisle® DX Flare Risk Index, Progentec Diagnostics, Inc |
| 0449U | Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2) | UNITY Carrier Screen™, BillionToOne Laboratory |
| 0450U | Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LCMS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides Being Deleted 10/01/2025 | M-inSight® Patient Definition Assay, Corgenix Clinical Laboratory, Sebia |
| 0451U | Oncology (multiple myeloma), LCMS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance Being deleted 10/01/2025 | M-inSight® Patient Follow-Up Assessment, Corgenix Clinical Laboratory, Sebia |
| 0452U | Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer | EarlyTect® Bladder Cancer Detection (EarlyTect® BCD), Promis Diagnostics, Inc |
| 0453U | Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA) | ColonAiQ®, Breakthrough Genomics, Singlera Genomics, Inc |

| | | |
|-------|---|---|
| 0454U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping. *Has an identical descriptor 0260U, 0264U | Chromosome Genome Mapping, UR Medicine Labs, Bionano Genomics, Inc |
| 0455U | Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected | Abbott Alinity™ m STI Assay, Abbott Molecular, Inc CT/NG/TV |
| 0457U | Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative | PFAS 9- Panel, Quest Diagnostics® Forever Chemicals |
| 0458U | Oncology (breast cancer), S100A8 and S100A9, by enzyme linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score | Auria®, Namida Lab, Inc |
| 0459U | β-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology | Elecsys® Total Tau CSF (tTau) and βAmyloid (1-42) CSF II (Abeta 42) Ratio, Roche Diagnostics Operations, Inc |
| 0460U | Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes | RightMed® Oncology Gene Report, OneOme® LLC |
| 0461U | Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes | RightMed® Oncology Medication Report, OneOme® LLC |
| 0462U | Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary | Salimetrics® Salivary Melatonin Profile (Circadian Phase Assessment), Salimetrics® Clinical Laboratory, Salimetrics®, LLC |

| | | |
|-------|---|--|
| 0463U | Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker | Proofer '7 HPV mRNA E6 and E7 Biomarker Test, Global Diagnostics Labs, LLC, PreTect AS, a Mel-Mont Medical, Inc, wholly owned subsidiary |
| 0464U | Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result | Cologuard Plus™, Exact Sciences Laboratories, LLC, Exact Sciences Corporation |
| 0465U | Oncology (urothelial carcinoma), DNA, quantitative methylation specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative | UriFind® Urothelial Carcinoma Assay, DiaCarta, Inc, AnchorDx |
| 0466U | Cardiology (coronary artery disease [CAD]), DNA, genome wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease | CardioRisk+, Gene by Gene, Ltd, OpenDNA, Ltd |
| 0467U | Oncology (bladder), DNA, next generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden | UroAmp MRD, Convergent Genomics, Inc |
| 0468U | Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis | NASHnext™ (NIS4™), Labcorp |
| 0469U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and | IriSight™ CNV Analysis, Variantyx Inc, |

| | | |
|-------|--|--|
| | aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination | |
| 0470U | Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma | HPV-SEQ Test, Sysmex Inostics, Inc |
| 0471U | Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin fixed paraffin-embedded (FFPE), predictive, identification of detected mutations | CRCdx® RAS Mutation Detection Kit, EntroGen, Inc |
| 0472U | Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semi-qualitative, blood, reported as predictive evidence of early Sjogren's syndrome | Early Sjögren's Syndrome Profile, Immco Diagnostics, Inc |
| 0473U | Oncology (solid tumor), next generation sequencing (NGS) of DNA from formalin-fixed paraffin embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden | xT CDx, Tempus AI, Inc |
| 0474U | Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene | GeneticsNow® Comprehensive Germline Panel, GoPath Diagnostics, Inc |
| 0475U | Hereditary prostate cancer related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent | ProstateNow™ Prostate Germline Panel, GoPath Diagnostics, Inc |

| | | |
|-------|---|--|
| | probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer | |
| 0476U | Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder | RightMed® Mental Health Gene Report, OneOme, LLC |
| 0477U | Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes | RightMed® Mental Health Medication Report, OneOme, LLC |
| 0478U | Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection | Lung HDPCR™, Protean BioDiagnostics |
| 0479U | Tau, phosphorylated, pTau217 | ALZpath pTau217, Neurocode USA, Inc, Quanterix/ALZpath |
| 0480U | Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification | Bacteria, Viruses, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid (MSCSF), Mayo Clinic, Laboratory Developed Test |
| 0481U | IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions) | IDH1, IDH2, and TERT Mutation Analysis, NextGeneration Sequencing, Tumor (IDTRT), Mayo Clinic, Laboratory Developed Test |
| 0482U | Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt1/PlGF, with risk of | Preeclampsia sFlt1/PlGF Ratio (PERA), Mayo Clinic, Laboratory Developed Test |

| | | |
|-------|---|--|
| | progression for preeclampsia with severe features within 2 weeks | |
| 0483U | Infectious disease (<i>Neisseria gonorrhoeae</i>), sensitivity, ciprofloxacin resistance (<i>gyrA</i> S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance | Ciprofloxacin Susceptibility of <i>Neisseria gonorrhoeae</i> , MedArbor Diagnostics, SpeedX, Inc |
| 0484U | Infectious disease (<i>Mycoplasma genitalium</i>), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance | Macrolide Resistance of <i>Mycoplasma genitalium</i> , MedArbor Diagnostics, SpeedX, Inc |
| 0485U | Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden | Caris Assure™, Caris MPI, Inc d/b/a Caris Life Sciences® |
| 0486U | Oncology (pan-solid tumor), next generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction | Northstar Response™, BillionToOne Laboratory, BillionToOne, Inc |
| 0487U | Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy corrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability | Northstar Select™, BillionToOne Laboratory, BillionToOne, Inc |
| 0488U | Obstetrics (fetal antigen noninvasive prenatal test), cellfree DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected | UNITY Fetal Antigen™ NIPT, BillionToOne |
| 0489U | Obstetrics (single-gene noninvasive prenatal test), cellfree DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to | UNITY Fetal Risk Screen™, BillionToOne Laboratory, BillionToOne, Inc |

| | | |
|-------|---|--|
| | determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia) | |
| 0490U | Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma associated antigen, CD34 and CD45 protein biomarkers, peripheral blood | CELLSEARCH® Circulating Melanoma Cell (CMC) Test, Menarini Silicon Biosystems Inc |
| 0491U | Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood | CELLSEARCH® ER Circulating Tumor Cell (CTC-ER) Test, Menarini Silicon Biosystems Inc |
| 0492U | Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker expressing cells, peripheral blood | CELLSEARCH® PDL1 Circulating Tumor Cell (CTCPD-L1) Test, Menarini Silicon Biosystems Inc |
| 0493U | Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using next generation sequencing, plasma, reported as percentage of donor derived cell-free DNA | Prospera™, Natera™ |
| 0494U | Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative | Rh Test, Natera™ |
| 0495U | Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer | Stockholm3, BioAgilytix Diagnostics |

| | | |
|-------|--|---|
| 0496U | Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk | ColoScape™ PLUS, DiaCarta, Inc |
| 0497U | Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer | OncoAssure™ Prostate, DiaCarta, Inc |
| 0498U | Oncology (colorectal), next generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation | OptiSeq™ Colorectal Cancer NGS Panel, DiaCarta, Inc |
| 0499U | Oncology (colorectal and lung), DNA from formalin-fixed paraffin embedded (FFPE) tissue, next generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection | OptiSeq™ Dual Cancer Panel Kit, DiaCarta, Inc |
| 0500U | Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.1189_118-2del, S56F, S621C) | QClamp® Plex VEXAS UBA1 Mutation Test, DiaCarta, Inc |
| 0501U | Oncology (colorectal), blood, quantitative measurement of cell free DNA (cfDNA) | QuantiDNA™ Colorectal Cancer Triage Test, DiaCarta, Inc |
| 0502U | Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV | QuantiVirus™ HPV E6/E7 mRNA Test for Cervical Cancer, DiaCarta, Inc |
| 0503U | Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (pTau217, np-tau217, pTau217/nptau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques | PrecivityAD2™, C2N Diagnostics, LLC |

| | | |
|-------|---|--|
| 0504U | Infectious disease (urinary tract infection), identification of 17 pathogenic organisms, urine, realtime PCR, reported as positive or negative for each organism | Urinary Tract Infection Testing, NxGen MDx LLC |
| 0505U | Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism | Vaginal Infection Testing, NxGen MDx LLC |
| 0506U | Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus | EndoSign® Barrett's Esophagus Test, Cyted Health Inc |
| 0507U | Oncology (ovarian), DNA, whole genome sequencing with 5hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected | Avantect Ovarian Cancer Test, ClearNote® Health |
| 0508U | Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell free DNA with risk for active rejection | VitaGraft™ Kidney Baseline + 1st Plasma Test, Oncocyte Corporation Deleted 01/01/2026 |
| 0509U | Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection | VitaGraft™ Kidney Subsequent, Oncocyte Corporation Deleted 01/01/2026 |
| 0510U | Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole transcriptome data, reported as probability of predicted molecular subtype | PuriSTSM, Tempus AI, Inc |
| 0511U | Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug | PARIS, Tempus AI, Inc, Tempus AI, Inc (by its wholly owned subsidiary SEngine Precision Medicine, LLC) |
| 0512U | Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffinembedded (FFPE) tissue, reported as increased or | Tempus p-MSI, Tempus AI, Inc |

| | | |
|-------|--|--|
| | decreased probability of MSI-high (MSI-H) | |
| 0513U | Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker | Tempus p-Prostate, Tempus AI, Inc |
| 0514U | Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL) | Procise ADL™, ProciseDx Inc |
| 0515U | Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL) | Procise IFX™, ProciseDx Inc |
| 0516U | Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status | MyGenVar Pharmacogenomics Test, Geisinger Medical Laboratories |
| 0517U | Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications | PrecisView® CNS, Phenomics Health™ Inc |
| 0518U | Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications | SyncView® Pain, Phenomics Health™ Inc |
| 0519U | Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation | SyncView® PainPlus, Phenomics Health™ Inc |

| | | |
|-------|---|---|
| 0520U | Therapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications | SyncView® Rx, Phenomics Health™ Inc |
| 0521U | Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood Effective 01/01/2025 | Seronegative Rheumatoid Arthritis Panel, KSL Diagnostics-Beutner Laboratories, Inc, KSL Biomedical, Inc |
| 0522U | Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiquantitative, blood Effective 01/25/25 | Tissue Specific Markers for Early Diagnosis of Sjogren's Disease, KSL Diagnostics, Inc |
| 0523U | Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change | oncoReveal™ CDx, Pillar Biosciences, Inc |
| 0524U | Obstetrics (preeclampsia), sFlt1/PIGF ratio, immunoassay, utilizing serum or plasma, reported as a value | PreClara™ Ratio sFlt-1/PIGF, Thermo Fisher Scientific |
| 0525U | Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug | 3D Predict™ Ovarian, KIYATEC®, Inc |
| 0526U | Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time | CXCL10 Urine Test, One Lambda™, Inc |
| 0527U | Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected | Abbott Alinity™ m HSV 1 & 2 / VZV Assay, Abbott Molecular, Inc |
| 0528U | Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria | BIOFIRE® FILMARRAY® Pneumonia (PN) Panel, bioMérieux |

| | | |
|-------|--|---|
| 0529U | Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE | Lifetime Genomics Risk Assessment, VTE, GenomicMD, Inc |
| 0530U | Oncology (pan-solid tumor), ctDNA, utilizing plasma, next generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy number alterations, with therapy association | LiquidHALLMARK®, Lucence Health, Inc Considered a broad molecular profiling panel test. This is not 0409U. |
| 0531U | Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma | NeXGen™ Fungal/AFB NGS Assay, Eurofins Viracor, LLC, Eurofins Viracor, LLC |
| 0532U | Rare diseases (constitutional disease/hereditary disorders), rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, peripheral blood, buffy coat, saliva, buccal or tissue sample, results reported as positive or negative | Rapid Genome Sequencing Test, University of California San Francisco Genomic Medicine Laboratory |
| 0533U | Drug metabolism (adverse drug reactions and drug response), genotyping of 16 genes (ie, ABCG2, CYP2B6, CYP2C9, CYP2C19, CYP2C, CYP2D6, CYP3A5, CYP4F2, DPYD, G6PD, GGCX, NUDT15, SLC01B1, TPMT, UGT1A1, VKORC1), reported as metabolizer status and transporter function | UCSF Pharmacogenomics Panel, University of California San Francisco Genomic Medicine Laboratory |
| 0534U | Oncology (prostate), microRNA, single-nucleotide polymorphisms (SNPs) analysis by RT-PCR of 32 variants, using buccal swab, algorithm reported as a risk score | PROSTOX™ ultra, MiraDx, Inc |
| 0535U | Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative | PFAS Testing & PFASure®FT, National Medical Services (NMS Labs), Laboratory Developed Test |
| 0536U | Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status | Prenatal Detect RhD, Devyser Genomic Laboratories, Devyser AB |
| 0537U | Oncology (colorectal cancer), analysis of cell-free DNA for epigenomic patterns, next-generation sequencing, >2500 differentially methylated regions (DMRs), plasma, algorithm reported as positive or negative | Shield™, Guardant Health, Inc |

| | | |
|-------|--|---|
| 0538U | Oncology (solid tumor), next-generation targeted sequencing analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant | PredicineATLAS™ Assay, Predicine Inc |
| 0539U | Oncology (solid tumor), cell-free circulating tumor DNA (ctDNA), 152 genes, next-generation sequencing, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, copy number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant | PredicineCARE™ Assay, Predicine Inc |
| 0540U | Transplantation medicine, quantification of donor-derived cell-free DNA using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free DNA to determine probability of rejection | AlloSure®, CareDx® Laboratory, CareDx®, Inc |
| 0541U | Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score | HDL Reverse Cholesterol Transport Panel with pCAD Score, Quest Diagnostics® |
| 0542U | Nephrology (renal transplant), urine, nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of BK virus (human polyomavirus 1) using real-time PCR and serum creatinine, algorithm reported as a probability score for allograft injury status | myOLARIS™-KTdx, Olaris®, Inc |
| 0543U | Oncology (solid tumor), next-generation sequencing of DNA from formalin-fixed paraffin-embedded (FFPE) tissue of 517 genes, interrogation for single-nucleotide variants, multi-nucleotide variants, insertions and deletions from DNA, fusions in 24 genes and splice variants in 1 gene from RNA, and tumor mutation burden | TruSight™ Oncology Comprehensive, Illumina, Inc |
| 0544U | Nephrology (transplant monitoring), 48 variants by digital PCR, using cell-free DNA from plasma, donor-derived cell-free DNA, percentage reported as risk for rejection | VitaGraft™ Kidney 2.0, Oncocyte Corporation 01/01/2026 |
| 0545U | Acetylcholine receptor (AChR), antibody identification by immunofluorescence, using live cells, reported as positive or negative | AChR Live Cell-Based Assay, Neurocode USA |

| | | |
|-------|---|--|
| 0546U | Low-density lipoprotein receptor-related protein 4 (LRP4), antibody identification by immunofluorescence, using live cells, reported as positive or negative | LRP4 Cell-Based Assay, Neurocode USA, Inc |
| 0547U | Neurofilament light chain (NfL), chemiluminescent enzyme immunoassay, plasma, quantitative | Neurofilament Light Blood Test, Neurocode USA, Inc, Fujirebio Diagnostics, Inc |
| 0548U | Glial fibrillary acidic protein (GFAP), chemiluminescent enzyme immunoassay, using plasma | Glial Fibrillary Acidic Protein Blood Test, Neurocode USA, Inc, Fujirebio Diagnostics, Inc |
| 0549U | Oncology (urothelial), DNA, quantitative methylated real-time PCR of TRNA-Cys, SIM2, and NKX1-1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (UTUC) | Bladder CARE™, Pangea Laboratory LLC |
| 0550U | Oncology (prostate), enzyme-linked immunosorbent assays (ELISA) for total prostate-specific antigen (PSA) and free PSA, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer | ClarityDx Prostate, Protean BioDiagnostics Deleted 01/01/2026 |
| 0551U | Tau, phosphorylated, pTau217, by single-molecule array (ultrasensitive digital protein detection), using plasma | LucentAD p-Tau 217, Quanterix Corporation Deleted 01/01/2026 |
| 0552U | Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophectoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder | PGT-M, Igenomix®, Part of Vitrolife Group™, Igenomix® |
| 0553U | Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested | Smart PGT-A Plus, Igenomix®, Part of Vitrolife Group, Thermo™, Fisher Scientific |
| 0554U | Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from trophectoderm biopsy for aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality | Smart PGT-SR, Igenomix®, Part of Vitrolife Group, Thermo™, Fisher Scientific |

| | | |
|-------|--|---|
| | control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested | |
| 0555U | Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested | Smart PGT-SR Plus, Igenomix®, Part of Vitrolife Group, Thermo™, Fisher Scientific |
| 0556U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | HealthTrackRx Bronchitis, HealthTrackRx, Thermo Fisher Scientific |
| 0557U | Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for Atopobium vaginae, Gardnerella vaginalis, Megasphaera types 1 and 2, bacterial vaginosis associated bacteria-2 and -3 (BVAB-2, BVAB-3), Mobiluncus species, Trichomonas vaginalis, Neisseria gonorrhoeae, Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei), Herpes simplex viruses 1 and 2, vaginal fluid, reported as detected or not detected for each organism | HealthTrackRx Vaginitis, HealthTrackRx, Thermo Fisher Scientific |
| 0558U | Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker (BF7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression | IGoCheck™ (Blood-Based Colorectal Cancer Test), Milagen, Inc |
| 0559U | Oncology (breast), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker (BF9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression | MammoCheck™ (Blood-Based Breast Cancer Test), Milagen, Inc |
| 0560U | Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood and tumor tissue, baseline assessment for design and construction of a personalized variant | Haystack MRD™ Baseline, Quest Diagnostics® |

| | | |
|-------|--|--|
| | panel to evaluate current MRD and for comparison to subsequent MRD assessments | |
| 0561U | Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood, subsequent assessment with comparison to initial assessment to evaluate for MRD | Haystack MRD™ Monitoring, Quest Diagnostics® |
| 0562U | Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (SNVs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free DNA, plasma, reported as presence of actionable variants | PGDx elio™ plasma focus Dx, Personal Genome Diagnostics Inc |
| 0563U | Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative | BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel – Respiratory Menu, bioMérieux |
| 0564U | Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative | BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel – Sore Throat Menu, bioMérieux |
| 0565U | Oncology (hepatocellular carcinoma), next-generation sequencing methylation pattern assay to detect 6626 epigenetic alterations, cell-free DNA, plasma, algorithm reported as cancer signal detected or not detected | EarlyDx MethylScan™ HCC, EarlyDiagnostics Laboratory, EarlyDiagnostics, Inc |
| 0566U | Oncology (lung), qPCR-based analysis of 13 differentially methylated regions (CCDC181, HOXA7, LRRC8A, MARCHF11, MIR129-2, NCOR2, PANTR1, PRKCB, SLC9A3, TBR1_2, TRAP1, VWC2, ZNF781), pleural fluid, algorithm reported as a qualitative result | EPISEEK™ MPE (Malignant Pleural Effusion Detection Test), Precision Epigenomics Inc, |
| 0567U | Rare diseases (constitutional/heritable disorders), whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants | Genomic Unity® 2.0, Variantyx, Inc |

| | | |
|-------|--|---|
| 0568U | Neurology (dementia), beta amyloid (AB40, AB42, AB42/40 ratio), tau-protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology | LucentAD™ Complete, Quanterix Corporation |
| 0569U | Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (>20000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate May be covered for Medicare plans if guidelines are met | Guardant Reveal™, Guardant Health, Inc |
| 0570U | Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison | i-STAT TBI, Abbott Point of Care |
| 0571U | Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants | LiquidHALLMARK® ctDNA and ctRNA, Lucence Health, Inc |
| 0572U | Oncology (prostate), high-throughput telomere length quantification by FISH, whole blood, diagnostic algorithm reported as risk of prostate cancer | ProsTAV®, Life Length S.L. |
| 0573U | Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastricsin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous | Amplified Sciences PanCystPro™, Amplified Sciences, Inc |
| 0574U | Mycobacterium tuberculosis, culture filtrate protein-10-kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MS) | NanoDetect-TB™, NanoPin Technologies, Inc |
| 0575U | Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes (miR-122, miR-885, miR-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection Effective 10/01/2025 | HepatoTrack™, LuminoDx Laboratory, |

| | | |
|-------|---|--|
| 0576U | Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free DNA (cfDNA) by whole genome next generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score Effective 10/01/2025 | OmniGraf® Liver, Eurofins Transplant Genomics, LLC |
| 0577U | Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode, reported as likelihood of malignancy Effective 10/01/2025 | GlycoKnow™ Ovarian, InterVenn Biosciences |
| 0578U | Oncology (cutaneous melanoma), RNA, gene expression profiling by realtime qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence 10/01/2025 | Merlin™ Test, SkylineDx USA, Inc, |
| 0579U | Nephrology (diabetic chronic kidney disease), enzyme linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigen-like (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline 10/01/2025 | Promarker®D, Proteomics International USA, Proteomics International Pty Ltd |
| 0580U | Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG Effective 10/01/2025 | iDart™ Lyme IgG ImmunoBlot Kit, ID-FISH Technology, Inc |
| 0581U | Transplantation medicine, antibody to non-human leukocyte antigens (non- HLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported 10/01/2025 | Autoantibody to Non- Human Leukocyte Antigen (non-HLA), Mayo Clinic Jacksonville |
| 0582U | Rare diseases (constitutional disease/hereditary disorders), rapid whole genome DNA sequencing for single nucleotide variants, insertions/ deletions, copy number variations, blood, saliva, tissue sample, variants reported 10/01/2025 | Rapid Whole Genome Sequencing, Mayo Clinic |

| | | |
|-------|---|--|
| 0583U | Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results(List separately in addition to code for primary procedure) Add-on. Use in conjunction with 0582U Effective 10/01/2025 | Rapid Genome Sequencing Family Member Comparator, Mayo Clinic |
| 0584U | Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking induced conformational conversion, qualitative Code with identical clinical descriptor, see 0035U Effective 10/01/2025 | RT-QuIC Prion, CSF, Mayo Clinic |
| 0585U | Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability | Labcorp® Plasma Complete™, Labcorp, Laboratory Developed Test |
| 0586U | Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene | RNA Salah Targeted Expression Panel, Moffitt Cancer Center Advanced Diagnostics Laboratory |
| 0587U | Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LCMS/ MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects Effective 10/01/2025 | SafeDrugs, Astraerus Lab, LLC, Quantlio Technologies |
| 0588U | Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split-well multiplex reverse transcription loop-mediated isothermal amplification (RTLAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days | TriVerity™, Inflammatrix™, Inc |

| | | |
|-------|---|--|
| 0589U | Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LCMS/ MS), plasma or serum, quantitative Effective 10/01/2025 | PFAS (Forever Chemicals) Panel 2 – 24 PFAS, Quest Diagnostics® |
| 0590U | Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism Effective 10/01/2025 | BIOTIA-ID™ Urine NGS Assay, Biotia Inc |
| 0591U | Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer Effective 10/01/2025 | MiCheck® Prostate, Minomic®, Inc |
| 0592U | Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin embedded (FFPE) tumor tissue, results report clinically significant variant(s) Effective 10/01/2025 | Aventa Lymphoma, Aventa Genomics, LLC |
| 0593U | Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected Effective 10/01/2025 | Taq Array Card Urinary Tract Infection PCR Panel, SoftCell Laboratories LLC, Doc Lab Inc |
| 0594U | Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis Effective 10/01/2025 | IVD CAPSULE PSP – Rapid Sepsis Test, Abionic SA |
| 0595U | Infectious disease (tropical fever pathogens), vectorborne and zoonotic pathogens, including 2 viruses (Chikungunya virus and Dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (Leptospira species), and 1 parasite with species differentiation (Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale), real-time RTPCR, whole blood, each pathogen reported | BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel, bioMérieux |

| | | |
|-------|---|---|
| | as detected or not detected Effective 10/01/2025 | |
| 0596U | Neurology (Alzheimer disease), plasma, 3 distinct isoform-specific peptides (APOE2, APOE3, and APOE4) by liquid chromatography with tandem mass spectrometry (LCMS/ MS), reported as an APOE proteotype Effective 10/01/2025 | Precivity-ApoE™, C2N Diagnostics, LLC |
| 0597U | Oncology (breast), RNA expression profiling of 329 genes by targeted next generation sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffin embedded (FFPE) tissue, algorithmic analyses to determine tumor-recurrence risk score Effective 10/01/2025 | AidaBreast™, PreludeDx™, Prelude Corporation |
| 0598U | Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels Effective 10/01/2025 | inFoods® IBS, Ethos Laboratories, Biomerica |
| 0599U | Oncology (pancreatic cancer), multiplex immunoassay of ICAM1, TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm reported as positive or negative Effective 10/01/2025 | PancreaSure™, Immunovia, Inc |
| 0600U | Infectious disease (wound infection), identification of 65 organisms and 30 antibiotic resistance genes, wound swab, real-time PCR, reported as positive or negative for each organism Effective 01/01/2026 | FidaLab Molecular Wound Infection Test, FidaLab LLC |
| 0601U | Infectious disease (periprosthetic joint infection), analysis of 11 biomarkers (alpha defensins 1–3, Creactive protein, microbial antigens for Staphylococcus [SPA, SPB], Enterococcus, Candida, and C. acnes, total nucleated cell count, percent neutrophils, RBC count, and absorbance at 280 nm) using immunoassays, hematology, clinical chemistry, synovial fluid, and diagnostic algorithm reported as a probability score Effective 01/01/2026 | Synovasure® Comprehensive PJI Test Panel with Syn Tuition™, CD Laboratories, Inc, division of Zimmer Biomet, CD Diagnostics, Inc, a division of Zimmer Biomet |

| | | |
|-------|---|--|
| 0602U | Endocrinology (diabetes),insulin (INS) gene methylation using digital droplet PCR, insulin, and Cpeptide immunoassay, serum, Hemoglobin A1c immunoassay, whole blood, algorithm reported as diabetes-risk score Effective 01/01/2026 | Diabetes Risk Test, Kihealth Inc® Laboratory |
| 0603U | Drug assay, presumptive, 77 drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS), results reported as positive or negative Effective 01/01/2026 | SLL Comprehensive Drug Analysis, Soft Landing Labs, Soft Landing Labs |
| 0604U | Allergy and immunology (chronic recurrent angioedema), 4 bradykinin peptides, liquid chromatography and tandem mass spectrometry (LC-MS/ MS), whole blood, quantitative Effective 01/01/2026 | Bradykinin, Quantitative, by LC-MS/MS, Virant Diagnostics, Inc |
| 0605U | Allergy and immunology (hereditary alpha tryptasemia), DNA, analysis of TPSAB1 gene copy number variation using digital PCR, whole blood, results reported with genotype specific interpretation of alpha-tryptase copy number and algorithmic classification as normal or abnormal Effective 01/01/2026 | Tryptase Gene Copy Number Analysis by dPCR, Virant Diagnostics, Inc |
| 0606U | Hematology (red cell membrane disorders), RBCs, osmotic gradient ektacytometry, whole blood quantitative Effective 01/01/2026 | Osmotic Gradient Ektacytometry, Cincinnati Children's Clinical Laboratories, RR Mechatronics |
| 0607U | Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 31 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations Effective 01/01/2026 | EMMA (Endometrial Microbiome Metagenomic Analysis), Igenomix®, Igenomix® USA |
| 0608U | Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 10 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations (Do not report 0608U in conjunction with 0607U) Effective 01/01/2026 | ALICE (Analysis of Infectious Chronic Endometritis), Igenomix®, Igenomix® USA |

| | | |
|-------|--|--|
| 0609U | Oncology (prostate), immunoassay for total prostate-specific antigen (PSA) and free PSA, serum or plasma, combined with clinical features, algorithm reported as a probability score for clinically significant prostate cancer Effective 01/01/2026 | ClarityDX Prostate, Protean BioDiagnostics, Nanostics Inc |
| 0610U | Infectious disease (antimicrobial susceptibility), phenotypic antimicrobial susceptibility testing of positive blood culture using microfluidic sensor technology to quantify bacterial growth response to multiple antibiotic types, reporting categorical susceptibility (susceptible, susceptible dose dependent, intermediate, resistant), minimum inhibitory concentration, and interpretive comments Effective 01/01/2026 | LifeScale Gram Negative Kit (LSGN) with the LifeScale AST system, Affinity Biosensors, LLC |
| 0611U | Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result Code with identical clinical descriptor, is 0612U Effective 01/01/2026 | HelioHCC™ Strat, Helio Genomics® |
| 0612U | Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result Code with identical clinical descriptor, see 0611U. Effective 01/01/2026 | HelioHCC™ Trace, Helio Genomics® |
| 0613U | Oncology (urothelial carcinoma), DNA methylation and mutation analysis of 6 biomarkers (TWIST1, OTX1, ONECUT2, FGFR3, HRAS, TERT promoter region), methylation-specific PCR and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma Effective 01/01/2026 | AssureMDx™, Vesica Health® Inc |

REFERENCES:

Akbani, R., Becker, K. F., Carragher, N., Goldstein, T., de Koning, L., Korf, U., Liotta, L., Mills, G. B., Nishizuka, S. S., Pawlak, M., Petricoin, E. F., 3rd, Pollard, H. B., Serrels, B., & Zhu, J. (2014). Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. *Molecular & cellular proteomics : MCP*, 13(7), 1625–1643. <https://doi.org/10.1074/mcp.0113.034918>

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 226: Screening for Fetal Chromosomal Abnormalities. 2020.

American Medical Association. (2024). *CPT Proprietary Laboratory Analyses (PLA) codes: Long Descriptors*. Retrieved October 10, 2024, from <https://www.ama-assn.org/system/files/cpt-pla-codes-long.pdf>.

American Medical Association (2025, April 1). *CPT® Proprietary Laboratory Analyses (PLA) Codes: Short Descriptors*. Retrieved May 1, 2025, from <https://www.ama-assn.org/system/files/cpt-pla-codes-short.pdf>

Argilés et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2020. 31(10):1291-305.

Article-Billing and Coding: Biomarkers for Oncology (A52986), (n.d.) <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52986>. Last accessed 05/12/2025.

Article-Billing and Coding: Influenza Diagnostic Tests (A59055), (n.d.) <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59055>. Last accessed 02/03/2025.

Article- Billing and Coding: MolDX: Blood Product Molecular Antigen Typing (A57155), (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38249&ver=18&bc=0>. Last accessed 01/21/2025.

Article-Billing and Coding: In Vitro Chemosensitivity & Chemoresistance Assays (A56771). (n.d.) <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56871&ver=19&>. Last accessed 01/21/2025.

Article-Billing and Coding: KidneyIntelX and KidneyIntelX.dkd Testing (A59595) (n.d.) <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59595&ver=3>. Last accessed 10/31/2024.

Article - Billing and Coding: MOLDX: Molecular Diagnostic Tests (MDT) (A56853). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56853>. Last accessed 10/05/2024.

Article - Billing and coding: MOLDX: NRAS Genetic Testing (A57486). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57486> Last accessed 10/03/2024.

Article- Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58720>. Last accessed 10/16/2024

Article - Billing and Coding: MOLDX: FDA-Approved KRAS Tests (A55162). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55162> Last accessed 10/01/2024.

Article - Billing and Coding: MOLDX: Pharmacogenomics Testing (A58324). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58324&ver=32> Last accessed 01/23/2025.

Article - Billing and coding: MOLDX: Repeat Germline Testing (A57331). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57331>. Last accessed 10/09/24.

Article - Billing and Coding: MOLDX: Proteomics Testing (A59646). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59646&ver=6>. Last accessed 10/07/2024.

Article - Billing and Coding: Molecular Pathology Procedures (A56199). (n.d.) <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56199>. Last accessed 10/13/2025.

Article- Billing and Coding: Multimarker Serum Tests Related to Ovarian Cancer Testing (A57020).(n.d.) <https://www.cms.gov/medicare-coverage-database/view/>

[article.aspx?articleid=57020&ver=5&bc=0](#). Last accessed 12/18/2024.

Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Johung, K. L., Kirilcuk, N., . . . Gurski, L. A. (2021). Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network*, 19(3), 329–359. <https://doi.org/10.6004/jnccn.2021.0012>

Blydt-Hansen TD;Sharma A;Gibson IW;Wiebe C;Sharma AP;Langlois V;Teoh CW;Rush D;Nickerson P;Wishart D;Ho J, T. (2020). *Validity and utility of Urinary CXCL10/CR immune monitoring in pediatric kidney transplant recipients*. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. <https://pubmed.ncbi.nlm.nih.gov/33034126/> Last accessed 10/09/2024.

Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Rúaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. *Clinical pharmacology and therapeutics*, 114(1), 51–68. <https://doi.org/10.1002/cpt.2903>

Brown, J. R., Freedman, A., & Aster, J. (2023, November 28). *Pathobiology of Burkitt lymphoma*. UpToDate. https://www.uptodate.com/contents/pathobiology-of-burkitt-lymphoma?search=Pathobiology+of+Burkitt+lymphoma&source=search_result&selectedTitle=1~117&usage_type=default&display_rank=1

Bureau for Medical Services. (n.d.). <https://dhhr.wv.gov/bms/Pages/default.aspx> Last accessed 10/01/2024.

Cayrefourcq L, Vincent M-C, Pierredon S, et al. Single circulating fetal trophoblastic cells eligible for non invasive prenatal diagnosis: The exception rather than the rule. *Sci Rep*. 2020;10:9861.

Centers for Disease Control and Prevention (CDC). Genomic and precision health: Evaluating genomic tests. Updated June 24, 2022. <https://www.cdc.gov/genomics/gtesting/>. Last accessed 10/18/2024.

Centers for Disease Control and Prevention (CDC). Genomics and your health: Pharmacogenomics. May 15, 2024. <https://www.cdc.gov/genomics-and-health/about/pharmacogenetics.html>. Last accessed 10/18/2024.

Chang L, Jiao H, Chen J, et al. Single-cell whole-genome sequencing, haplotype analysis in prenatal diagnosis of monogenic diseases. *Life Sci Alliance*. 2023;6(5):e202201761.

CHOP VEO-IBD Genetic Panel (Children's Hospital of Philadelphia). Symplr evidence: analysis. (2026, January 6). <https://evidence.hayesinc.com/report/pmr.chop6215>. Last accessed 01/21/2026

Clinical Laboratory Improvement Amendments (CLIA) | CMS. (n.d.). <https://www.cms.gov/regulations-and-guidance/legislation/clia> Last accessed 09/30/2024.

Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy. (2015). *Obstetrics and gynecology*, 126(3), e31–e37. <https://doi.org/10.1097/AOG.0000000000001051>

CRCDX® RAS Mutation Detection Kit – EntroGen, Inc. (n.d.). <https://entrogen.com/web3/crcdx-ras-mutation-detection-kit/>. Last accessed 10/10/24.

Drexler, R., Brembach, F., Sauvigny, J. et al. Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact. *acta neuropathol commun* 12, 9 (2024).

<https://doi.org/10.1186/s40478-024-01728-9>

EndeavorRx (Akili Interactive Labs Inc.) for Treatment of Attention-Deficit/Hyperactivity Disorder in Children: Symplr evidence analysis. (2023, January 18). <https://evidence.hayesinc.com/report/eeer.endeavorrx4972>. Last accessed 03/05/2026

Feizpour, A., Doecke, J. D., Doré, V., Krishnadas, N., Huang, K., Bourgeat, P., Laws, S. M., Fowler, C., Robertson, J., Mackintosh, L., Ayton, S., Martins, R., Rainey-Smith, S. R., Taddei, K., Ward, L., Stage, E., Bannon, A. W., Masters, C. L., Fripp, J., . . . Rowe, C. C. (2024). Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform. *EBioMedicine*, 109, 105405. <https://doi.org/10.1016/j.ebiom.2024.105405>

Grigorev, G., Lebedev, A., Wang, X., Qian, X., Maksimov, G., & Lin, L. (2023). Advances in microfluidics for single red blood cell analysis. *Biosensors*, 13(1), 117. <https://doi.org/10.3390/bios13010117>

Karimi, S., Zuccato, J.A., Mamatjan, Y. *et al.* The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. *Clin Epigenet* 11, 185 (2019). <https://doi.org/10.1186/s13148-019-0766-2>

Hayes Knowledge Center | symplr. (n.d.-c). <https://evidence.hayesinc.com/report/gte.oncotype2530>. Last accessed 10/10/2024.

Industry Standard Review

InterQual® 2024 Medicare: Molecular Diagnostics & Lab- Biomarkers Overview Novitas. Last accessed 01/27/2025.

InterQual® 2024, Jan. 2025 Release, CP:Molecular Diagnostics Comprehensive Genomic Profiling, Tumor Tissue. Last accessed 01/25/2025.

InterQual® 2024 CP:Molecular Diagnostics COVID-19 Testing. Last accessed 02/04/2025.

InterQual® 2024 Medicare: Molecular Diagnostics & Lab- Genetic Testing for Cardiovascular Disease. Last accessed 01/27/2025.

InterQual® 2024, Medicare:Molecular Diagnostics & Lab- In Vitro Chemosensitivity and Chemoresistance Assays Palmetto. Last accessed 02/03/2025

InterQual® 2024, Medicare:Molecular Diagnostics & Lab -MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia CGS. Last accessed 01/29/2025.

InterQual® 2024 Medicare:Molecular Diagnostics & Lab-MoIDX: Molecular Testing for Solid Organ Allograft Rejection Palmetto. Last accessed 01/29/2025.

InterQual® 2024 Medicare: Molecular Diagnostics and Lab- MoIDX: Repeat Germline Testing WPS. Last accessed 01/15/2025.

InterQual® 2024 Molecular Diagnostics & Lab -Molecular Pathology Procedures. Last accessed 01/15/2025.

InterQual® 2024 CP: Molecular Diagnostics Multi-Gene Panels for Hereditary Colorectal Cancer Syndromes. Last accessed 01/15/2025.

InterQual® 2024 CP: Molecular Diagnostics Noninvasive Prenatal Screening (NIPS). Last accessed 02/03/2025.

InterQual® 2024, CP:Molecular Diagnostics Pharmacogenomic Testing in NSCLC. Last accessed 02/03/

2025.

InterQual® 2024 CP: Molecular Diagnostics-Pharmacogenomic Testing for Psychotropic Medication Drug Response. Last accessed 01/23/2025.

InterQual® 2024, Nov. 2024 Medicare: Molecular Diagnostics & Lab Molecular Pathology Procedures Not Covered NGS. Last accessed 01/23/2025.

InterQual® 2025 Medicare: Molecular Diagnostics and Lab Colorectal Cancer Screening Tests NCD. Last accessed 05/09/2025.

LCD- Billing and Coding: KidneyIntelX and KidneyIntelX.dkd Testing (L39726). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39726>. Last accessed 11/01/2024.

LCD - BDX-XL2 (L37031). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37031&ver=35&bc=0>. Last accessed 01/10/2025

LCD- Biomarkers for Oncology (L35396). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35396&ver=220>. Last accessed 05/12/2025.

LCD-In Vitro Chemosensitivity & Chemoresistance Assays (L34554), (n.d), <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34554&ver=34>. Last accessed 01/21/2025.

LCD- MolDX: Blood Product Molecular Antigen Typing (L38249), (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38249&ver=18&bc=0>. Last accessed 01/01/25

LCD - MOLDX: Molecular Diagnostic Tests (MDT) (L36021). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36021&ver=48>. Last accessed 10/10/2024

LCD - MOLDX: Molecular Diagnostic Tests (MDT) (L36807). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36807&ver=43>. Last accessed 10/18/2024

LCD - MOLDX: Molecular Testing for detection of upper gastrointestinal metaplasia, dysplasia, and neoplasia (L39276). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39276&ver=5&bc=0>. Last accessed 01/10/2025.

LCD - MOLDX: NRAS Genetic Testing (L36335). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36335&ver=24>. Last accessed 01/10/2025.

LCD - MOLDX: Repeat Germline Testing (L38351). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38351&ver=8>. Last accessed 10/15/24.

LCD-MOLDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L39001). (n.d.) <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39001&ver=8>. Last accessed 10/16/24.

LCD - MOLDX: Pharmacogenomics Testing (L38394). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38394&ver=9&bc=0>. Last accessed 02/303/2025.

LCD-Multimarker Serum Tests Related to Ovarian Cancer Testing (L38371). (n.d.) <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38371&ver=12>. Last accessed 12/18/2024.

LCD - Urinary Biomarkers for Chronic Pain Management (L39616). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39616&ver=4&bc=0>. Last accessed 01/22/2025.

Lewis, C. M., & Vassos, E. (2020). Polygenic risk scores: from research tools to clinical instruments. *Genome*

medicine, 12(1), 44.

Man, Y., Wu, D. H., An, R., Wei, P., Monchamp, K., Goreke, U., Sekyonda, Z., Wulftange, W. J., Federici, C., Bode, A., Nayak, L. V., Little, J. A., & Gurkan, U. A. (2023). Microfluidic concurrent assessment of red blood cell adhesion and microcapillary occlusion: potential hemorheological biomarkers in sickle cell disease. *Sensors & Diagnostics*, 2(2), 457–467. <https://doi.org/10.1039/d2sd00095d>

Massenburg, D., Oldenberg, J., Sell, A., Krause, T., & Wells, A. F. (2017). Using the SLE-Key® Rule-Out test in clinical practice. *Lupus Open Access*, 02(02). <https://doi.org/10.35248/2684-1630.17.2.126>

National Comprehensive Cancer Network (NCCN). Breast Cancer Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. 2023.

National Comprehensive Cancer Network (NCCN). The NCCN clinical practice guidelines in oncology, colon cancer (Version 3.2021). 2021.

National Comprehensive Cancer Network (NCCN). Prostate Cancer Version 4.2022, NCCN Clinical Practice Guidelines in Oncology. 2022.

National Comprehensive Cancer Network (NCCN), NCCN Guidelines®: Myelodysplastic Syndromes, Version 3.2022, (2022).

Natera. Natera's Panorama non-invasive prenatal test now available for screening twin pregnancies. Press Release. San Carlos, CA: Natera; October 2, 2017.

NCD - Next Generation Sequencing (NGS) (90.2). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372>. Last accessed 10/10/2024.

NCD- Colorectal Cancer Screening Tests (210.3). (n.d.). <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=281&ncdver=7&bc=0>. Last accessed 05/09/2025 .

NeuroDiagnostics, LLC. Discern test. Rockville, MD: NeuroDiagnostics; 2020. Available at: <https://www.ndx-discern.com/discern/>. Accessed October 16, 2020.

Oncotype DX Breast DCIS Score (Exact Sciences): Symplr evidence analysis. (2024, February 16). <https://evidence.hayesinc.com/report/gte.oncotype2530>. Last accessed 03/05/2026

Oncotype DX Colon Recurrence Score (Exact Sciences): Symplr evidence analysis. (2024, June 21.). <https://evidence.hayesinc.com/report/gte.oncotype1980>. Last accessed 03/05/2026

Optum.(2024). Current Procedural Coding Expert, CPT® codes with Medicare Essential for Enhanced Accuracy. Last accessed 10/01/2024.

Park, J. W., Lee, K., Kim, E. E., Kim, S. I., & Park, S. H. (2023). Brain Tumor Classification by Methylation Profile. *Journal of Korean medical science*, 38(43), e356. <https://doi.org/10.3346/jkms.2023.38.e356>

Paulson KG, Carter JJ, ohnson LG, et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. *Cancer Res*. 2010;70(21):8388-97.

Paulson KG, Lewis CW, Redman MW, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. *Cancer*. 2017;123(8):1464-1474.

Samini M, Molet L, Fleury M, et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. *Br J Dermatol*. 2016;174(4):813-22.

Schimanski B, Krauchi R, Stettler J, et al. Fetal RHD screening in RH1 negative pregnant women: Experience in

Switzerland. *Biomedicines*. 2023;11(10):2646.

Suprun M, Getts R, Raghunathan R, et al. Novel Bead-Based Epitope Assay is a sensitive and reliable tool for profiling epitope-specific antibody repertoire in food allergy. *Sci Rep*. 2019;9(1):18425.

Sterling, K., & Christenson, S. (2025, May 1). *Tools for genetics and genomics: Gene expression profiling*. UpToDate. https://www.uptodate.com/contents/tools-for-genetics-and-genomics-gene-expression-profiling?search=Tools+for+genetics+and+genomics%3A+Gene+expression+profiling%E2%80%9D+%28Stein+and+Christenson%2C+2021%29&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

UpToDate. (n.d.-a). UpToDate. https://www.uptodate.com/contents/genetic-testing?search=Germline%20genetic%20testing&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1 Last accessed 11/04/24.

UpToDate. (n.d.). UpToDate. https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-alzheimer-disease?search=Wolk%20DA%2C%20Dickerson%20BC.%20Clinical%20features%20and%20diagnosis%20of%20Alzheimer%20disease.%20UpToDate%20%5Bonline%20serial%5D.%20Waltham%2C%20MA%3A%20UpToDate%3B%20reviewed%20November%202024%3B%20February%202025.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Last accessed 11/05/2025.

UpToDate. (n.d.-b). UpToDate. https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications?search=Germline%20genetic%20testing&source=search_result&selectedTitle=3%7E150&usage_type=default&display_rank=3

UpToDate. (n.d.-c). UpToDate. https://www.uptodate.com/contents/overview-of-pharmacogenomics?search=Germline%20genetic%20testing&source=search_result&selectedTitle=4%7E150&usage_type=default&display_rank=4

UpToDate. (n.d.-e). UpToDate. https://www.uptodate.com/contents/genetics-of-alzheimer-disease?search=whole%20genome%20sequencing%20with%205hmc%20enrichment&source=search_result&selectedTitle=7%7E150&usage_type=default&display_rank=7. Last accessed 10/31/2024.

UpToDate. (n.d.). UpToDate. https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-von-willebrand-disease?search=James%20P.%20Clinical%20presentation%20and%20diagnosis%20of%20von%20Willebrand%20disease.%20UpToDate%20%5Bonline%20serial%5D.%20Waltham%2C%20MA%3A%20UpToDate&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1 . Last accessed 10/31/2024.

UpToDate. (n.d.-b). UpToDate. https://www.uptodate.com/contents/approach-to-the-child-with-bleeding-symptoms?search=James%20P.%20Clinical%20presentation%20and%20diagnosis%20of%20von%20Willebrand%20disease.%20UpToDate%20%5Bonline%20serial%5D.%20Waltham%2C%20MA%3A%20UpToDate&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2. Last accessed 10/31/2024.

UpToDate. (n.d.-c). UpToDate. https://www.uptodate.com/contents/systemic-lupus-erythematosus-in-adults-overview-of-the-management-and-prognosis?search=SLE-key%20rule%20Out%20&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2

U.S. Food and Drug Administration (FDA). Elecsys β -amyloid (1-42)CSF II, Elecsys phospho-tau (181P) CSF. 510K no. K221842. SilverSpring, MD: FDA; December 7, 2022.

Versiti Diagnostic Laboratories. vonWillebrand Factor collagen binding (III and IV). Milwaukee, WI: Versiti;

2024. Available at: <https://versiti.org/diagnostic-labs-test-menu>. Last accessed 01/17/2025.

Wallace DJ, Alexander RV, O'Malley T, et al. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. *Lupus Sci Med*. 2019;6(1):e000349.

Wojno KJ, Baunoch D, Luke N, et al. Multiplex PCR based urinary tract infection (UTI) analysis compared to traditional urine culture in identifying significant pathogens in symptomatic patients. *Urology*. 2020;136:119-126.

Yliniemi A, Makikallio K, Korpimaki T, et al. Combination of PAPP-A, fhCG β , AFP, PIGF, sTNFR1, and maternal characteristics in prediction of early-onset preeclampsia. *Clin Med Insights Reprod Health*. 2015;9:13-20.

Youssef A, Righetti F, Morano D, et al. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. *Prenat Diagn*. 2011;31(12):1141-1146.

Yu DT, van Tubergen A. Diagnosis and differential diagnosis of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. *UpToDate* [online serial]. Waltham, MA: UpToDate;

Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. *NPJ Precis Oncol*. 2018;2:23.

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. *CA Cancer J Clin*. 2024; doi:10.3322/caac.21820

Douville C, Nobles C, Hwang HJ, et al. Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma. Poster presented at: ESMO Congress; September 9-13, 2022; Paris, France. Abstract 73P.

Beer TM. Examining developments in multicancer early detection: highlights of new clinical data from recent conferences. *Am J Manag Care*. 2021;27(19 Suppl):S347-S355.

RELATED POLICIES:

Clinical Drug Testing in Addiction Treatment Programs and Pain Management Programs ID 17249930

Experimental/Investigational Services Policy Stat ID 14533046

Genetic Testing for Hereditary Cancers: Breast, Ovarian, and Pancreatic ID 16843290

Non-invasive Prenatal Testing (NIPT) - Cell-Free DNA ID 14949798

Vaginitis Diagnostic Testing ID 14533208

POLICY HISTORY:

11/05/2024 New

01/01/2025 Coding Guidelines section updated to add additional Proprietary Lab codes 0001U-0046U, 0048U-0094U, 0096U-0103U, 0106U-0117U, 0119U-0247U, 0249U-0259U, 0261U-0263U, 0265U-0301U, 0303U-0350U, 0352U-0355U, 0358U-0364U, 0366U-0402U, 0404U-0406U, 0408U-0419U, 0428U. Deleted codes 0478U as deactivated as of 10/01/2024 and 0456U, as code deactivated 01/01/2025. Revised code descriptions for the following: 0351U, 0356U, 0403U. Changed CPT 0528U from not requiring precertification to requiring precertification in order to match PAL and CPT TOOL. Coverage policy section added the following notation: *If specific criteria is not indicated here for individual tests, The Health Plan will utilize InterQual Criteria or the appropriate Medicare NCD/LCD depending on product line.* Updated References

section. Updated Precertification sections and Exclusion sections with the additional codes.

06/01/2025 Updated 0080U to no precertification required. Added the new April 2025 codes 0531U-0551U. Added 0478U back to policy. Added coverage criteria for Rh Test by Natera, 0494U. Revised Proprietary names to the following codes: 0089U, 0095U, 0220U, 0288U, 0308U, 0309U, 0310U, 0393U, 0420U. Revised descriptions to the following codes: 0285U and 0365U. Moved the following codes from the exclusion section to the tests requiring precertification section: 0527U, 0331U, 0444U, 0454U, 0227U, 0439U, 0318U, 0332U, 0433U, 0047U, 0335U, 0336U, 0105U, 0407U, 0529U, 0409U, 0430U, 0119U, 0069U, 0068U, 0486U, 0487U, 0169U, 0523U, 0019U, 0313U, 0440U, 0494U, 0434U, 0460U, 0461U, 0339U, 0219U, 0449U, 0165U, 0178U. Noted the following codes are deleted: 0240U, 0241U, 0352U-as it is replaced by 81515, 0369U, 0370U, 0373U, 0374U, 0380U, 0428U. Removed reference to Somatic Mutation CRC and Xt testing as coding has been changed to 81445,81449. etc..

07/28/ 2025 Added July 1, 2025 codes 0552U-0574U. Noted code deletion for Codes being deleted as of 7/1/2025. Noted codes being deleted for 10/01/2025 0450U, 0451U. Added 81599 and 81479 in regards to MCED (multicancer early detection) testing being not covered. Added note as to Cancerguard™ by Exact Sciences as not covered as currently in clinical trial. 2025 revisions to descriptions completed. As presented in MDOC 7/23/2025.

10/13/2025 for 1/1/2026 policy update. Added language: "Covered only for certain Medicare plans at this time." for codes 0178U, 0227U, 0423U, 0175U, 0333U, 0388U, 0419U. Moved code 0025U, 0119U, 0179U, 0261U, 0263U, 0275U, 0287U, 0313U, 0341U to Exclusions/Not Covered section . Added may be covered for Medicare plans only language for 0119U. Moved code 0320U and 0552U, 0563U, 0564U, 0567U, 0571U, 0582U, and 0583U to Requires Precertification section. Moved code 0256U, 0399U to No Precertification Required section. Added language for that code 0345U must be billed for all lines of business for GeneSight® Psychotropic test. Added info for GeneSight ADHD, GeneSight Analgesic, GeneSight MTHFR would use 81479 or 81291 respectively and may not be covered depending on reason for test and line of business. Added for code 0569U Guardant Reveal that it may be covered for Medicare plans providing guidelines are met. Added language under Coverage Guidelines requiring providers to bill the appropriate code for the appropriate tests as assigned by CMS and AMA. Added the new codes for October 2025 and January 2026, 0575U-0613U. Noted codes being deleted for October 2025 and January 2026: 0033U, 0131U, 0132U, 0135U, 0361U, 0508U, 0509U, 0544U, 0550U, 0551U. Removed the codes deleted back in July 2025: 0240U, 0241U, 0369U, 0370U, 0373U, 0374U.

12/3/2025 UM Committee removed Cologuard Plus 0464U from requiring precertification for 2/1/2025.

03/05/2026 Added information under exclusions section and updated sources regarding CHOP VEO-IBD Genetic Panel (Children's Hospital of Philadelphia).

DISCLAIMER:

CPT codes are copyright of the American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

The services listed in this policy is not meant to be an all-inclusive list of Proprietary Lab services available. Proprietary Laboratory codes not found in this policy does not necessarily imply coverage or non-coverage of a service.

This policy is intended to serve as a guideline only and does not constitute medical advice, any guarantee of payment, plan pre-authorization, an explanation of benefits, or a contract. This policy is intended to address medical necessity guidelines that are suitable for most individuals. Each individual's unique clinical situation

may warrant individual consideration based on medical records. Individual claims may be affected by other factors, including but not necessarily limited to state and federal laws and regulations, legislative mandates, provider contract terms, and THP's professional judgment. Reimbursement for any services shall be subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification, and utilization management guidelines. Unless otherwise noted within the policy, THP's policies apply to both participating and non-participating providers and facilities. THP reserves the right to review and revise these policies periodically as it deems necessary in its discretion, and it is subject to change or termination at any time by THP. THP has full and final discretionary authority for its interpretation and application. Accordingly, THP may use reasonable discretion in interpreting and applying this policy to health care services provided in any particular case.

No part of this policy may be reproduced, stored in a retrieval system, transmitted, in any shape or form or by any means, whether electronic, mechanical, photocopying, or otherwise, without express written permission from THP. When printed, this version becomes uncontrolled. For the most current information, refer to the following website: healthplan.org.